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Abstract

TISSUE ENGINEERING COMPOSITE BIOMIMETIC GELATIN SPONGES FOR
BONE REPAIR
By Isaac Anthony Rodríguez, M.S.
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy in Biomedical Engineering at Virginia Commonwealth University.

Virginia Commonwealth University, 2013

Major Director: Dr. Gary L. Bowlin
Professor, Biomedical Engineering

The field of tissue engineering aims to develop viable substitutes with the ability to
repair and regenerate the functions of damaged tissue. Common practices to supplement
bone regeneration in larger defects include bone graft biomaterials such as autografts,
allografts, xenografts, and synthetic biomaterials. Autologous bone grafting is the current
gold-standard procedure used to replace missing or damaged bone. However, these grafts
have disadvantages such as donor site morbidity, limited availability, and the need for a
secondary surgery. The focus of this study is to tissue engineer a lyophilized gelatin
composite sponge composed of hydroxyapatite (HA), chitin whiskers (CW), and
preparations rich in growth factors (PRGF) to provide sufficient structural support to the
defect site while enhancing the body’s own reparative capacity, ultimately eliminating the
need for autologous tissue harvesting or repeat operations.
xi

The present study investigates several in vitro evaluations on multiple compositions
of modified gelatin sponge scaffolds for use in bone graft applications. Gelatin sponges
were fabricated via freeze-drying, enhanced with PRGF, HA, and/or CW, and cross-linked
with 50 mM 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) either
during or post gelation. Initial evaluation of all scaffold combinations indicated that
scaffolds released contents up to 90 days, EDC cross-linking during gelation allowed for
more protein release, and had the ability to swell. Since the incorporation of PRGF, HA,
and CW increased cell infiltration, and production of cell-created mineral matrix over 90
days in culture, these scaffolds were further characterized. Freeze-dried gelatin sponges
enhanced with PRGF, HA, and CW and cross-linked during gelation with EDC (PHCE)
were mineralized (M) in 5x revised simulated body fluid (r-SBF) for 1 hour to create a
bone-like mineral surface. Gelatin EDC scaffold controls (GE), GE-M, PHCE, and PHCEM scaffolds were characterized for their ability to swell, mineralizing potential, surface
morphology, growth factor incorporation and release, uniaxial compression properties, and
cell attachment, proliferation, infiltration, and protein/cytokine secretion.. After
mineralization, scanning electron microscopy showed sparse clusters of mineral deposition
for GE-M scaffolds while PHCE-M scaffolds exhibited a more uniform mineral
deposition. Both GE and PHCE scaffolds were porous structures that swelled up to 50% of
their original volume upon hydration. Over 21 days incubation, PHCE-M scaffolds
cumulatively released about 30% of their original protein content, significantly more than
all other scaffolds. Multiplex Luminex assays confirmed the successful incorporation of
PRGF growth factors within PRGF sponges. For acellular uniaxial compression testing,
xii

PHCE-M scaffolds reported lower Young’s modulus values (1.3 - 1.6 MPa) when
compared to GE and GE-M scaffolds (1.6 – 3.2 MPa). These low modulus values were
comparable to values of tissue found in early stages of bone healing. DAPI (4',6diamidino-2-phenylindole) staining and imaging showed an increase in initial cell
attachment and infiltration of PHCE and PHCE-M scaffolds on day 1. GE-M scaffolds also
appeared to attach more cells than the GE control. MTS cell proliferation assay results
indicated that on days 4 and 7, PHCE scaffolds increased cell proliferation (compared to
GE controls). MTS also illustrated that the addition of a mineral coating increases and
decreases cell proliferation on GE-M and PHCE-M scaffolds, respectively. Multiplexer
analysis of MG-63 protein/cytokine secretion suggests that cells are responding in a bone
regenerative fashion on all scaffolds, as evidence of osteocalcin secretion. Little to no
secretion of osteopontin, IL-1β, and TNF-α demonstrates that scaffolds are not influencing
cells to secrete factors associated with bone resorption. The compressive mechanical
properties of cellularized scaffolds did not differ much from acellular scaffolds. The
collective results indicated increased cellular attachment, infiltration, and bone
regenerative protein/cytokine secretion by cells on GE-M scaffolds, which support the
addition of a bone-like mineral surface on GE scaffolds. Cellularized PHCE and PHCE-M
scaffolds report similar advantages as well as Young’s modulus values in the range of
native tissues present in the early stages of bone healing. The results of this study propose
that the developed PHCE and PHCE-M scaffolds exhibit good cellular responses and
mechanical properties for use in early bone healing applications.

xiii

1. ALTERNATIVE BONE GRAFTS – A CLINICAL NEED
1.1. INTRODUCTION
Healthy bone has the unique ability to spontaneously regenerate. However, bone
injuries, particularly large bone defects/injuries, lack the ability to heal and have a severely
limited reparative capacity ultimately requiring surgical intervention and replacement.
Autologous bone grafting is the current gold-standard procedure used to replace missing or
damaged bone and has been used for the regeneration of bone for multiple applications:
dental implants (restore area of a missing tooth), spinal fusion, and repairing broken bones
(that have bone loss or have not yet healed). Currently, there are more than 500,000 bone
grafting surgeries performed in the United States each year, averaging between $33,860 to
$37,227 per procedure, not including other expenses such as surgeon/anesthesiologist fees
and hospital/medication charges [1, 2].

Although autologous bone grafting produces

satisfactory results, these grafts carry the risk of donor site morbidity as well as limited
availability. Other grafting options such as synthetic materials (metals and ceramics) elicit
a foreign body response and are not biodegradable. The increasing number of bone grafts
performed in the U.S. annually, combined with the drawbacks of autografts, has created a
shortage of cadaver allografts and a need to increase musculoskeletal tissue donation. As a
result, there has been an increase in corporate interest in regards to developing alternative
bone grafting substitutes which include (but are not limited to) the use of natural, synthetic,
human, and animal-derived biomaterials. The sales of bone grafts and bone-graft
substitutes in the US have increased from 0.3 to 1.5 billion dollars from 1999 – 2009 with
1

increased spending on bone substitutes, platelet concentrators, bone morphogenetic
proteins, and more [1]. This dissertation will particularly focus on tissue engineering a
lyophilized (or freeze-dried) gelatin sponge enhanced with concentrated platelet-derived
growth factors and bone extracellular matrix (ECM) factors which may provide sufficient
structural support to the defect site while enhancing the body’s own reparative capacity,
ultimately eliminating the need for autologous tissue harvesting or repeat operations.

1.2. CURRENT TREATMENT OPTIONS FOR BONE GRAFTS
Common practices to supplement bone regeneration in larger defects include bone
graft biomaterials such as autograft (patient’s own bone), allograft (human cadaver bone),
xenograft (animal bone), and synthetic biomaterials (i.e. ceramics, cements, glasses,
metals, polymers, and composites) [2-6]. The most common hard tissue graft is an
autograft, whereby bone is taken from the patient’s own body and reimplanted into the
defect site. Autologous bone grafts harvested from patient donor sites are osteoconductive
(provide a scaffold where bone cells can proliferate), osteoinductive (induce proliferation
of undifferentiated cells and their differentiation into osteoblasts), and osteogenic (provide
a reservoir of skeletal stem and progenitor cells that can form new bone) [3]. Autografts
are the best material for bone repair because of their supreme histocompatibility without
the risk of disease transfer [4]. However, their limited availability, additional invasive
surgery, and significant donor site morbidity (as shown in Table 1.1) are all drawbacks
which encourage the development of alternative bone substitutes [3, 5-10]. The most
frequently used donor site for autologous bone grafts is cancellous iliac bone. Alternative
2

donor sites have been explored [11, 12], however even these suffer the same drawbacks
mentioned above.
Table 1.1 – Reported complication rates of harvesting iliac crest bone for autografts [10].
Reprinted with permission from Springer.

Allografts are an option for bone grafting because they are harvested from cadaver
donors which means they are readily available, can be prepared in various shapes/sizes and
there is no need to compromise or sacrifice the patient’s own bone (no donor site morbidity
or secondary surgery for harvesting). The main disadvantage of allografts is the potential
for disease transfer. Although, the allograft providers do their best to inactivate viruses,
3

there is still the possibility that not all infectious contents (such as blood and cellular
components) were sufficiently destroyed. Even if the processing and irradiation protocols
are successful in removing any threats for disease transfer, it is still possible for these
procedures to compromise the graft’s biomechanical and biochemical properties. The
overall challenge with allografts is to prepare well cleaned, sterile, and free of virus
implants, while maintaining the natural biologic and biomechanical properties of the tissue
[1, 13].
Xenografts are grafts derived from another species other than the host. For humans,
the most common xenografts are harvested from bovine bone [14]. Before implantation in
humans, the organic components of the graft are completely removed (to ideally eliminate
human rejection by the immune response) leaving only the inorganic portions which serve
as the natural architecture matrix and a source of calcium [15]. The disadvantages of
xenografts include potential disease transfer (similar to allografts), infection, and rejection
by the host immune system [16].
The field of tissue engineering “aims to restore function to or replace damaged or
diseased tissues through the application of engineering and biological principles” [17].
Given that each of the above mentioned grafts has their own distinct disadvantages,
synthetic biomaterial scaffolds that are biocompatible, biodegradable, porous, bioactive,
and mechanically stable have been the focus of research as alternative bone substitutes.
The use of polymeric scaffolds and tissue engineering techniques can achieve bone repair
while eliminating the need for autologous grafts. Most research has centered on developing
some form of a mineralized biomimetic scaffold that is biocompatible, mechanically
4

stable, has a moderate degradation rate over several months, and is osteogenic. These
biomimetic structures are typically composed of synthetic/natural polymers and some form
of calcium phosphates (usually hydroxyapatite, HA). Although many of these structures
contain the basic ECM components of bone, they lack enhancing osteogenic promoting
proteins and true three-dimensionality. Chapter 2 will provide a review of alternative bone
graft substitutes within the field of bone tissue engineering.

5

2. BACKGROUND INFORMATION

2.1. BONE: STRUCTURE AND REMODELING
Bone is a natural composite of collagenous organic matrix reinforced by an
inorganic mineral phase of HA whose structure is ultimately responsible for its functional
properties. Other components of bone include calcium phosphates, water, proteins, etc.
[18]. Natural bone is a complex and highly organized structure of parallel collagen
nanofibrils, and carbonated apatite (HA nanocrystals) located within the fibrils and
precipitated on their surface [18, 19]. These HA nanocrystals can be either platelet or
spindle shaped and up to about 200 nm long which creates a large surface area for effective
mineral exchange [20]. Type I collagen is the main organic component (composing about
90%) of mineralized ECM and is the foundation upon which minerals are deposited. The
ECM is the framework of each tissue which provides cues to promote cellular adhesion,
migration, differentiation, and proliferation. Cells continually produce, secrete, and modify
ECM components which attribute to a unique ECM structure and composition for each
tissue. Ultimately, the biomechanical properties and biological function is attributed to this
organic-inorganic nanocomposite bone ECM [21].
Bone undergoes continuous yet subtle remodeling in order to achieve its function.
The mineral components, such as calcium phosphates and HA are responsible for the
hardness of bone. The toughness and visco-elasticity is attributed to the soft organic
collagenous matrix [22]. At the cellular level, osteoblasts reside on the surfaces of bone
6

and are involved in the secretion of the osteoid (unmineralized organic matrix, mainly type
I collagen) and subsequent formation, mineralization, and organization of bone ECM.
Osteoblasts are also differentiated forms of progenitor cells (such as mesenchymal stem
cells and stromal cells) that are recruited to the site in need of bone rebuilding [23]. Once
mature osteoblasts rebuild the area in need they either undergo apoptosis or become
integrated within the deposited matrix and become osteocytes which maintain the bone
matrix by controlling the activity of osteoblasts and osteoclasts [24]. Osteoclasts are large,
multinucleated phagocyte-like cells formed from the fusion of macrophages, which adhere
to the bone surface and are responsible for mineral dissolution and the degradation of the
organic phase (bone resorption) [21]. It is known that bone remodeling is regulated
through an osteoblast-osteoclast coupling system in which both cell types signal each other
to maintain the balance of bone rebuilding and resorption at the appropriate sites. Any
imbalance of this system can cause diseases, such as osteoporosis. Specifically with bone
rebuilding, little is known about the role of osteoclasts with regards to signaling osteoblast
recruitment. It has been reported that platelet-derived growth factor bb (PDGF-bb) is one
such factor released by osteoclasts that control osteoblast chemotaxis [25]. Within the last
five years, a new bone cell type has been identified and studied. Like most tissues, the
bone-lining tissues (endosteum and periosteum) contain a population of resident tissue
macrophages (OsteoMacs) that are likely to play a role in bone healing and bone
homeostasis (through regulating osteoblast function). OsteoMacs are a significant
population within the osteal microenvironment (constitute about one sixth of the total cell
population) confirming that cells other than osteoblasts reside on the bone surface [26-28].
7

Figure 2.1 – The basic multicellular unit of bone remodeling [21]. Reprinted with
permission from Elsevier.

Mineralization of bone first occurs at nucleation sites located within the hole zone
regions of the organic matrix of bone (collagen fibrils). This region is a volume of space
where mineral crystals (calcium phosphates, Ca-P) are deposited from the extracellular
fluid. Since mineralization occurs in these hole zones, it suggests that the threedimensional geometry and the composition of the fibrils (mineral-filled collagen) are
factors in mineralization; specifically suggesting that nucleation sites are located in the
collagen fibrils within the hole zone regions [29]. This initial nucleation process occurs at
independent sites within the collagen fibrils and does not damage or disrupt the matrix
structure. After the initial nucleation, there is continuous formation of Ca-P crystals due to
secondary nucleation of the already formed crystals. Also during this stage, primary
nucleation sites within the hole zone which did mineralize are still able to nucleate Ca-P
crystals. Throughout the mineralization process Ca-P undergo a phase transformation from
8

a solution (extracellular fluid) to a solid phase (Ca-P crystals). It is important to note that
the increase in mineralization is due to the increase in the number of crystals rather than
the increase in the size of the crystals already formed [29]. Mineralization of a polymer
scaffold occurs in the same manner as described above for native bone. Mineral nucleation
occurs first on the polymer surface and then mineral crystals multiply on the nucleated
mineral [30].

This native mineralization process is the underlying principles behind

biomimetic mineralization described later.

2.2. NORMAL BONE HEALING
The process in which normal bone healing occurs is divided into three main stages:
inflammatory, repair, and remodeling. To initiate the inflammatory stage, a hematoma is
developed at the injury site. This fibrin clot provides the framework for inflammatory cells
(such as monocytes and macrophages) and fibroblasts to infiltrate the site of injury which
results in granulation tissue formation, vascularization, and migration/differentiation of
mesenchymal stem cells (MSCs) [31]. It is known that a variety of growth factors
contribute to the migration and differentiation of MSCs into bone building cells
(osteoblasts). These growth factors are supplied by multiple sources, including the various
migrating cells and the platelets from the clot [23]. The repair stage begins within 1 to 2
weeks by removing damaged cells and replacing the weak fibrin clot with a more
mechanically stable structure (callus). During the repair stage, cartilage and collagen are
formed and subsequently mineralized. Eventually the callus ossifies (endochondral
ossification) and becomes woven bone (newly formed bone only present in early
9

development or during bone repair) [23, 31, 32]. In the remodeling stage, the bone is
restored to its original shape, structure, and mechanical strength. Here, the woven bone is
remodeled into lamellar bone via osteoclast and osteoblast coupling as previously
described. A popular area of bone tissue engineering is the focus on the repair and
remodeling stage, specifically the differentiation of MSCs into osteoblasts and the
osteoblasts ability to attach and produce organic-inorganic matrix.

Figure 2.2 - Fracture healing: inflammatory and repair stages. Although remodeling is a
stage of fracture healing, it is also a process that is continuously occurring in the body at
all times and therefore is not included in the immediate healing diagram above [32].
Reprinted with permission from Elsevier.
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Intuitively, as the stages of bone healing progress, the mechanical properties of the
tissue increases. As displayed in Figure 2.3, Leong et al. reported the changes in
mechanical properties of bone fracture calluses in rats, specifically recording the
indentation modulus of granulation tissue (0.55 ± 0.04 MPa), cartilage (1.36 ± 0.078 MPa),
newly formed woven bone (36.5 ± 5.84 MPa), and cortical bone (7.2 ± 0.61 GPa).
Although this study reports the indentation modulus and not elastic modulus, the general
relationship of mechanical properties of healing bone can be extracted. For rat femur
fracture callus healing cortical bone was approximately 200x, 5,300x, and 13,000x higher
modulus values than woven bone, cartilage, and granulation tissue, respectively.
Fabrication of scaffolds for this dissertation will cater to the lower mechanical properties
of the early stages of bone healing (granulation tissue and cartilage) rather than newly
formed or mature bone since the goal is to create a scaffold that mimics early healing and
promotes osteoblast matrix deposition.
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Figure 2.3 - Measurement of indentation modulus of rat fracture calluses at progressive
stages in bone healing [33]. Reprinted with permission from Oxford University Press.

2.3. BONE TISSUE ENGINEERING
Tissue engineering focuses on developing viable substitutes that are able to repair
and regenerate the functions of damaged tissue [34]. Specifically, bone tissue engineering
requires a scaffold to temporarily support cell adhesion and direct their growth into bone
tissue until the scaffold is completely replaced by the new tissue [35]. Cells respond to
environmental cues such as composition, topographical structure, mechanical properties,
and presence of biological factors. Therefore, within tissue engineering, cellular response
and subsequent tissue growth are dependent on the characteristics of the scaffolding
system. Since cellular growth depends on the characteristics of the scaffolding system, it is
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important to fabricate scaffolds that mimic the structure and composition of natural bone
ECM [36].
Several scaffold fabrication techniques for tissue engineering applications have
been developed using biodegradable synthetic and/or natural polymers with the potential to
incorporate bioactive molecules. Some of these include freeze-drying [18], solvent
casting/particulate leaching [30, 37], gas foaming/particulate leaching [5, 7, 9],
plates/meshes [38], solvent casting/salt leaching [39], salt leaching/solid-liquid phase
separation [40], and electrospinning [8, 21, 36, 41-47]. Important factors in the success of
bone tissue engineering scaffolds include biocompatibility, degradability, porosity,
osteoconductivity, and mechanical stability. Biocompatibility and degradability can be
controlled by the polymer(s) used. Osteoconductivity and mechanical stability can
potentially be enhanced by the growth of a bone-like mineral (BLM) on the scaffold
surface prior to cell seeding [37]. Porosity can be controlled by altering parameters during
different scaffold fabrication techniques. Porosity is an important design criterion for
scaffolds, as a highly porous scaffold will allow for neovascularization throughout the
construct [48]. It has been demonstrated that scaffolds with increased pore size enhance
osteoblast proliferation and differentiation throughout the scaffold as a result of increased
oxygen and nutrient transport, and neovascularization [49-51].
Polymers (both natural and synthetic) are a promising category of potential
biomaterials used for bone tissue engineering [3]. Natural polymers attract special interest
in tissue engineering since they have high mineralization potential, are highly bioactive,
biocompatible, biodegradable, and natural substrates where cells can attach, proliferate,
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and function [52]. One main criticism of natural polymers is that (when used alone) they
lack mechanical integrity and are more quickly degraded. Synthetic polymers have been
specifically fabricated for medical applications because they are versatile and free of
potential contamination [53]. The advantage of using synthetic polymers for scaffolding is
that they are more mechanically stable and able to undergo chemical modifications in order
to improve cell adhesion, cell function, and mineralization. However, synthetic polymers
generally lack bioactivity without these modifications which led to interest in developing
composite scaffolds combining osteoconductive materials with polymer-based materials
[3].
There has also been widespread use of Ca-P (such as HA) for bone tissue
engineering applications [5]. The major advantages of HA include (i) it is the major
inorganic component of bone matrix, (ii) they have affinity to many adhesive proteins, and
(iii) they are osteoconductive materials directly involved in bone cell differentiation and
mineralization process [22, 46].

Even though inorganic HA materials have many

advantages, they have limited use as tissue engineering scaffolds because they are brittle
[42]. However, combining the bone-bioactivity of the inorganic materials with the
structural integrity of the organic polymers introduces an organic-inorganic composite
scaffold specifically tailored for bone tissue engineering. Composite organic-inorganic
scaffolds have the potential to satisfy the complex scaffold designs criteria such as material
composition, architecture, structural mechanics, surface properties, and degradation
properties and products [22].In addition, calcium-based ceramics undergo a phase
transformation and precipitate on the surfaces as Ca-P crystals. This sequence of events
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leads to the formation of a carbonate-containing BLM layer on the surface which enhances
osteoconductivity and is essential in creating a bond with the living host bone [54-56].
Collagen and HA are popular materials when investigating bone scaffolds since
their composites mimic the ECM of natural bone [18, 57-60]. More recently, gelatin
(denatured collagen) has been used as a replacement for collagen since it is less expensive,
easier to obtain, and contains similar functional groups which enhance cellular response
[61]. Gelatin also contains specific binding domains, such as the RGD sequence, which are
related to cell attachment [62]. Freeze-dried gelatin sponges have many advantages
because they can be designed to fit any size defect/injury site, have the ability to swell and
fill a void space, degrade controllably in a range of rates (due to various cross-linking
methods) to ensure drug release and mechanical stability, and can be easily modified by
incorporating various osteoconductive/osteoinductive materials (i.e. minerals, growth
factors, proteins, etc.). These porous scaffolds are fabricated without the use of harsh
organic solvents which addresses one of the drawbacks of alternative scaffold fabrication
methods. The addition of bioactive inorganic HA to freeze-dried gelatin sponges creates a
bone-like ECM scaffold which allows a more controlled drug delivery system and
increases cellular attachment, proliferation, alkaline phosphatase activity, and osteocalcin
production [63-65]. HA also has the ability to bind to a variety of molecules, including
proteins. As a result, scaffolds incorporated with HA provide a more favorable
environment through increased adsorption of serum adhesion proteins such as fibronectin
and vitronectin [66]. Enhanced cellular responses have also been observed with the
addition of other minerals (β-tricalcium phosphate, dicalcium phosphate dihydrate),
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polymers (gellan, poly-lactide-co-glycolide) and proteins (bone morphogenetic protein,
Wnt1 inducible signaling pathway protein) in combination with HA [67-69].
Other additions such as chitin whiskers (CW, i.e. chitin nanocrystals) and plateletrich plasma (PRP) have been used to increase the mechanical integrity (CW), bioactivity
(CW and PRP), and osteogenic potential of scaffolds (PRP) [70-72]. Chitin is the second
most abundant biopolymer next to cellulose and possesses many favorable properties such
as non-toxicity, high crystallinity, biocompatibility and biodegradability. Acid-treatment of
chitin can dissolve regions of low lateral order, resulting in elongated rod-like
nanocrystals, termed “whiskers”. CW are an emerging and novel nanofiller that have been
shown to bring about reinforcing effects on both synthetic and natural polymeric
structures. The biocompatibility and biodegradability also make it one of the most
promising nanofillers. In recent years, experiments studying CW have increased due to its
availability, nontoxicity, and ability to mechanically reinforce polymer nanocomposites
and enhance cell proliferation [70, 73-77].
Platelet-rich plasma (PRP) is a simple and cost-effective method for collecting and
concentrating autologous platelets for the purpose of activating and releasing their growth
factor-rich alpha and dense granules. Upon collecting PRP, platelet-poor plasma (PPP) can
also be obtained simultaneously. PPP contains little to no amounts of growth factors and
high concentrations of fibrinogen. Results of numerous studies have demonstrated the
versatility and effectiveness of PRP within wound healing, skin engineering,
ligament/tendon engineering, cartilage repair, bone regeneration, and more [71, 78-83].
Particularly with bone regeneration, the addition of PRP has been reported to increase bone
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density/mineralization, vascularization, and osteogenesis [71, 72, 84-86]. Preparation rich
in growth factors (PRGF, a bioactive lyophilized version of PRP) contains high
concentrations of growth factors such as platelet-derived growth factor (PDGF),
transforming growth factor-β (TGF-β), insulin-like growth factor-1 (IGF-1), vascular
endothelial growth factor (VEGF), epidermal growth factor (EGF), fibroblast growth factor
(FGF), hepatocyte growth factor (HGF), and more [87-89]. PRGF also contains cell
adhesive proteins such as fibronectin and vitronectin. Many of these factors are known for
their angiogenic potential, however, their ability to enhance bone repair has also been
studied. In relation to bone remodeling, these growth factors and proteins elicit a favorable
cellular response which supports the incorporation of PRGF within scaffolds intended for
bone tissue engineering [90-98]. The bone remodeling functions for some of these
molecules are summarized in Table 2.1. PRGF can be easily incorporated into scaffolds at
desired concentrations which ultimately allow consistent reproducible bioactive scaffolds.
The incorporation of PRGF within gelatin sponges, the general combination of CW and
PRGF, and the combination of PRGF with HA and/or CW in gelatin sponges are all areas
that have yet to be explored.
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Table 2.1 - Role of PRGF components in bone remodeling [87-94, 97-104].
Function
MSC and progenitor cell recruitment, proliferation,
PDGF
migration and differentiation into osteoblasts
MSC differentiation, increased production of collagen
TGF-β
and mineral matrix
IGF-1
Osteoblast proliferation and differentiation
VEGF
Angiogenesis, endochondral ossification
Angiogenesis, osteoblast proliferation, increases
HGF
osteoblast BMP-2 production
EGF
MSC migration and osteoblast differentiation
Angiogenesis, osteoprogenitor cell proliferation,
differentiation, and expression of osteogenic markers
FGF
and mineralization
Fibronectin, Enhance formation of focal adhesions by osteoblasts,
Vitronectin osteoblast migration

Several cell types can be used for in vitro evaluation of bone tissue engineering.
Some include undifferentiated osteoprogenitor cells (mesenchymal stem cells, stromal
cells, and periosteal cells) and already differentiated osteoblasts. For this dissertation, MG63 cells were used to evaluate in vitro cellular response. MG-63 cells are human
osteoblast-like cells derived from an osteosarcoma. These cells behave similar to
osteoblasts with their attachment, migration, proliferation, and organic-inorganic matrix
production. MG-63 cells are commonly used for evaluation of biocompatibility and
cellular response to bone regenerative environmental cues, such as scaffolds [65, 67, 105109].
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2.4. BIOMIMETIC MINERALIZATION
As previously mentioned, a BLM layer formed on the surface of biomaterials is an
essential requirement for the material to bond to the living bone and enhance
osteoconductivity. In 1990, Kokubo et al. developed an acellular solution, simulated body
fluid (SBF), with ionic concentrations approximately equal to those of human blood
plasma [110]. The most commonly used SBF is conventional (c-SBF). Oyane et al. revised
the c-SBF and prepared new SBFs that were closer to the ionic concentration of blood
plasma. The SBFs developed were revised (r-SBF), ionic (i-SBF), and modified (m-SBF)
[111]. Of these, r-SBF has the overall closest ionic concentrations to that of total blood
plasma (Table 2.2).

Table 2.2 - Ionic concentrations of blood plasma [112]. Reprinted with permission from
John Wiley and Sons.

SBF is used to induce mineral nucleation, creating a BLM layer on the surface of
materials [110]. This technique can be used for complex porous scaffolds since the apatite
crystals are generated from an aqueous solution. Immersion of scaffolds in SBF is an easy
task and does not require any special equipment. It has been found that the BLM
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(carbonated HA) layer generated resembles natural bone mineral in its nano-crystal size
and low crystallinity [40]. SBF has been widely used for biomimetic BLM coating on
bioinert materials to directly mimic the process of mineralization in native bone and to
predict the in vivo bioactivity of the material [9, 30, 37, 38, 41, 43, 45, 113]. It has been
found that if a material is able to form a BLM layer in short periods when immersed in
SBF, then it will bond to living bone in short periods [114].
The overall focus of this study was to characterize the first attempts of a tissue
engineered freeze-dried gelatin composite sponge enhanced with PRGF, HA, and CW to
provide sufficient structural support to the defect site while enhancing the body’s own
reparative capacity, ultimately eliminating the need for autologous tissue harvesting or
repeat operations. Composite gelatin sponges were further modified via mineralization and
characterized to understand scaffold release, cell response, and mechanical properties. The
central hypothesis of this study is that a biodegradable lyophilized gelatin composite
sponge will serve as a bioactive structure to facilitate osteoblast attachment, migration, and
matrix secretion while exhibiting controlled release and stable mechanical properties in the
range of tissues present in early bone healing.
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3.1. ABSTRACT
The purpose of this study was to perform a number of preliminary in vitro
evaluations on an array of modified gelatin gel sponge scaffolds for use in a bone graft
application. The gelatin gels were modified through the addition of a number of
components which each possess unique properties conducive to the creation and
regeneration of bone: a PRGF, HA, and CW. PRP therapy is an emerging practice that has
proven effective in a number of clinical applications, including enhancing bone repair
through improved deposition of new bony matrix and angiogenesis. As such, the inclusion
of PRGF in our gelatin scaffolds was intended to significantly enhance scaffold bioactivity,
while the addition of HA and CW were anticipated to increase scaffold strength.
Additionally, the gelatin sponges, which readily dissolve in aqueous solutions, were
subjected to 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) crosslinking either during or post gelation to control their rate of degradation. Scaffolds were
evaluated in vitro with respect to compressive strength, change in mass, protein release,
and MG-63 cellular interaction, with results demonstrating the potential of the gelatin
sponge scaffold for use in the regeneration of bone.

3.2. INTRODUCTION
As previously mentioned, healthy bone has the unique ability to spontaneously
regenerate. However, if the diseased or damaged area exceeds a certain size, bone grafting
is needed to regenerate the tissue [115]. Common practices to supplement bone
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regeneration in larger defects include bone graft biomaterials such as autografts, allografts,
xenografts, and synthetic biomaterials (i.e. ceramics, cements, glasses, metals, polymers,
and composites) [3, 116-119]. Since each of the above mentioned grafts have their own
distinct

disadvantages,

synthetic

biomaterial

scaffolds

that

are

biocompatible,

biodegradable, porous, bioactive, and mechanically stable have been the focus of research
as alternative bone substitutes.
The present study aimed to evaluate the release kinetics, difference in mass,
mechanical properties, and cellular responses of multiple combinations of composite
freeze-dried gelatin sponges. PRGF, CW, and/or HA were incorporated into the gelatin
sponges and cross-linked during gelation or after lyophilization to increase the scaffolds’
overall compatibility as a bone tissue engineering substitute. The goal of this study is to
create a scaffold that mimics the microenvironment of early bone healing. In turn, this will
foster a hospitable environment for osteoblast attachment, migration, and secretion of bone
matrix, which will lead to woven bone formation and remodeling.

3.3. MATERIALS AND METHODS

3.3.1. Fabrication of gelatin composite sponges
All scaffolds were fabricated with a base solution of 30 mg/ml gelatin (Type B
from Bovine skin, Sigma) in deionized (DI) water. For composite scaffolds, a total amount
of 10 mg/ml of PRGF, HA, and/or CW were weighed, added to the 30 mg/mL gelatin
solution, then sonicated if necessary (Table 3.1). Materials included HA nanopowder
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(particle size < 200 nm (BET), Sigma-Aldrich), CW (prepared by following a published
protocol [74]),

PRGF (created using published protocol [88]), and1-Ethyl-3-(3-

dimethylaminopropyl)carbodiimide hydrochloride (EDC, Thermo Scientific). To create
PRGF, fresh human whole blood from 3 donors was purchased, combined, and centrifuged
(SmartPReP® 2) to create PRP. PRP then underwent a freeze (-70°C) – thaw (37°C) –
freeze (-70°C) cycle to ensure platelet lysis and activation. Frozen PRP was then
lyophilized to obtain a dry PRGF powder to be weighed and incorporated within the
gelatin solution [88].
4 mL of the prepared gelatin or gelatin composite solution was pipetted into a 35 x
10 mm Petri dish, refrigerated at 4°C overnight to gel, and then slowly frozen at -15°C
overnight, -20°C for 4 hours, and -70°C for 4 hours. Frozen gel composites were
lyophilized for 24 hours then cross-linked for 18 hours at room temperature in 50 mM
EDC in ethanol [120-123]. To analyze the effect of an alternative cross-linking method,
another set of solutions were made and 50 mM EDC was added directly to the composite
solution before gelation. This process allowed for simultaneous gelation and cross-linking
(scaffolds denoted as +EDC). After gelation, scaffolds were frozen and lyophilized as
previously described. Using a Miltex biopsy punch, 6 mm discs were punched and used
for all experiments.
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Table 3.1 - Scaffold components and fabrication concentrations.

+HA
+CW
+HA+CW
+PRGF
+PRGF+HA
+PRGF+CW

amount (mg/mL) added to gelatin
solution
10
10
5 (HA) and 5 (CW)
10
5 (PRGF) and 5 (HA)
5 (PRGF) and 5 (CW)

+PRGF+HA+CW 3.33 (PRGF), 3.33 (HA), and 3.33 (CW)

sonicated
yes
yes
yes
no
yes (HA) then PRGF added
yes (CW) then PRGF added
yes (HA+CW) then PRGF
added

3.3.2. Mass loss
Two 6 mm scaffold punches were weighed as a unit for initial dry mass. Scaffolds
were then disinfected (30 minutes ethanol followed by three 10 minute washes of 1x
Phosphate Buffered Saline, PBS – Quality Biological, Inc., pH 7.4) and transferred to a 48well plate (two discs per well, n=3). 500 µL of Dulbecco’s modified Eagle’s medium
(DMEM, HyClone) high glucose containing 10% fetal bovine serum (FBS, Atlanta
Biologicals) and 1% penicillin/streptomycin (HyClone) was added to each well. The two
scaffolds per well were incubated in media at 37°C and 5% CO2 with media changes every
7 days. Scaffolds were removed and weighed as a unit every 7 days up to 90 days.
Hydrated scaffolds were massed and compared to original dry weights as a percentage to
determine percent increase in scaffold mass. Scaffolds were air-dried post 90 day culture
and compared to original dry weights to determine overall mass loss.
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3.3.3. Protein release
To determine total protein content of each 6 mm scaffold disc, triplicates of one
non cross-linked 6 mm discs of each scaffold type was immersed in 500 µL of 1x PBS.
Uncross-linked scaffolds completely degraded within minutes at room temperature. Since
scaffolds are primarily comprised of gelatin, the released components are detectable using
a general protein assay. Protein was quantified using a Pierce BCA Protein Assay (Thermo
Scientific) with 8 serial dilutions of bovine serum albumin as standards (from 2 to 0
mg/mL). Briefly, 25 µL of PBS containing the degraded scaffold contents was added to
200 µL of working reagent in a 96-well plate. The well plate was then incubated at 37°C
for 30 minutes, cooled to room temperature, and absorbance measured at 562 nm using a
SpectraMax Plus 384 Microplate Spectrophotometer (Molecular Devices).
Scaffold release kinetics was studied by quantifying protein release from each
scaffold over a period of 90 days. Triplicates of one 6 mm disc of each cross-linked
scaffold type were incubated in 500 µL of 1x PBS at 37°C with PBS replaced every 3
days. After 1, 4, 7, 10, 14, 21, 28, 56, and 90 days the PBS containing released scaffold
contents in each well was analyzed for protein content using the Pierce BCA Protein Assay
described above.
3.3.4. Cell attachment, migration and matrix production
Triplicates of 6 mm discs of each scaffold composition were seeded with 50,000
osteoblast-like cells (MG-63 cells from a human osteosarcoma) and incubated at 37°C and
5%

CO2

in

DMEM

high

glucose

media
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containing

10%

FBS

and

1%

penicillin/streptomycin with media changes every three days. After 1, 28, and 90 days,
scaffolds were fixed in 10% Buffered Formalin Acetate (Fisher Scientific) and stored at
4°C until preparation for scanning electron microscopy (SEM) and fluorescent staining.
For uniaxial compression testing, scaffolds were tested directly after being removed from
the incubator.

Scanning electron microscopy
Scaffolds were removed from formalin, briefly rinsed in PBS and water, and then
subjected to ethanol dehydration (10 minute soaks in 30, 50, 70, 90, and 100 % ethanol,
subsequently). Samples were air dried overnight, mounted on aluminum stubs, sputter
coated in gold for 70 seconds, and examined using a JEOL JSM-5610LV scanning electron
microscope.

DAPI staining
Scaffolds were removed from formalin, immersed in a 30% sucrose solution in DI
water for 48 hours at 4°C to ensure displacement of all air bubbles, suspended in premium
frozen section compound (VWR), and frozen at -70°C overnight. 60 µm slices were
cryosectioned using a Cryostat (Thermo) and transferred to microscope slides.
Cryosectioned samples were then stained with 4’-6-diamidino-2-phenylindole (DAPI)
stain for 5 minutes and imaged using a UV fluorescent microscope to display the location
of cell nuclei.
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Alizarin Red S staining
Alizarin Red S (ARS) is a dye that selectively binds to calcium salts. ARS staining
was used to quantify scaffold mineral content by modifying a published protocol [112].
ARS was performed on the 6 mm scaffold punches after 1, 28, and 90 days incubation in
media with and without cells. After incubation scaffolds were stained with 40 mM Alizarin
Red (Sigma-Aldrich) for 30 minutes then washed with DI water to remove any unbound
stain. Scaffolds were then transferred to a 2 mL microcentrifuge tube containing 1.5 mL of
50% acetic acid to destain for 1 hour at room temperature. 500 µL of the solubilized stain
was added to 600 µL of 1 M NaOH to adjust the pH to 4.1. 200 µL of this solution was
pipetted into a 96-well plate and absorbance read at 550 nm using a SpectraMax Plus 384
Microplate Spectrophotometer.
3.3.5. Uniaxial compression testing
Uniaxial compression testing was performed on acellular and cellularized 6 mm
scaffold discs after 1, 28, and 90 days incubation in media. Mechanical testing was
conducted by attaching an indenter (cylindrical, 2 mm diameter, plane-ended, stainless
steel) to a MTS Bionix 200 Mechanical Testing System instrument with a 100 N load cell
(MTS Systems Corp., USA, Figure 3.1). Indentation was performed perpendicular to the
scaffold surface at the center of each scaffold disc. The discs were placed on a flat metal
surface and kept hydrated with PBS. The indenter was lowered to the surface of the
scaffolds and the following parameters were used: test speed of 0.5 mm/min, data
acquisition rate of 10 Hz, a preload of 0.015 N, and a max indenter displacement of 90% of
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the scaffold thickness. Peak load was calculated by the MTS software TestWorks 4.0.
Many scaffolds at later time points did not register a preload until later in the testing which
resulted in the indenter moving through the entire scaffold until reaching the maximum
load of 100 N when the intender contacted the metal plate. In these instances, the
maximum peak load plateau, just before the maximum load was reached, was extracted
from the graph and reported.

Figure 3.1 - Compressive mechanical testing set up with indenter.
3.3.6. Statistical analysis
Statistical analysis was performed using JMP IN 9 statistical software (SAS
Institute) to determine significant differences. Analysis of the data was based on a KruskalWallis one-way analysis of variance on ranks and a Tukey-Kramer pairwise multiple
29

comparison procedure. The results are presented in mean ± standard deviation (SD).
Unless otherwise specified all samples were run at a minimum of triplicate (n=3) to ensure
statistical significance (p<0.05).
3.4. RESULTS AND DISCUSSION

3.4.1. Mass loss
Figure 3.2 below shows the percent difference in mass between original dry
scaffold weight, days 1, 28, 90, and dry post-culture scaffold weight. When comparing the
two methods of cross-linking, scaffolds cross-linked post-fabrication absorbed more media
and gained more mass (between 1500-2800 %) than scaffolds that were cross-linked
during gelation (+EDC, between 500-1600 %). Upon comparing post cross-linked
scaffolds at days 1, 28, and 90, the gelatin scaffolds showed significantly higher (p<0.05)
mass increase than any other scaffold type. Also, CW and all scaffolds containing PRGF
showed statistically significant (p<0.05) increases in mass at day 90 when compared to day
1, suggesting that these scaffolds continuously absorbed media throughout the culture
period. For +EDC scaffolds, most scaffold types reached their maximum weight after day
1 and did not increase in mass over 90 days incubation. Only CW and PRGF+HA+CW
scaffolds showed significant (p<0.05) mass increases. On days 1 and 28, HA scaffolds had
significantly higher (p<0.05) percent differences in mass than all other scaffolds except for
HA+CW and PRGF+HA+CW scaffolds, respectively. After 90 days, the percent difference
in mass of HA scaffolds was only significantly higher than gelatin, PRGF, and PRGF+CW
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scaffolds. Overall, the post cross-linked scaffolds swelled and absorbed more media than
the +EDC scaffolds.

Figure 3.2 - Percent difference in mass.

Table 3.2 below compares the original dry pre-culture mass (Pre) to the dry, post
90 day culture mass (Post) of each scaffold type for both cross-linking methods. All
scaffolds that were cross-linked post-fabrication significantly increased in dry mass after
culture. For +EDC scaffolds, all scaffolds containing HA showed significant increases in
mass while PRGF scaffolds significantly decreased in dry mass. The reason for this
increase in mass following a 90 day culture period is not completely understood, especially
since each scaffold demonstrated protein release throughout its culture duration that would
be indicative of an overall mass loss. It is hypothesized that the gelatin sponges absorbed
FBS-resident proteins present in the complete media in which they were incubated, which,
upon subsequent drying and removal of any liquid prior to the post-culture massing
remained trapped within the scaffold’s structure. The swelling and media absorption seen
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when dry scaffolds were introduced into culture media demonstrated that the gelatin
scaffolds had a tremendous hygroscopic potential, thereby making it feasible that large
amounts of FBS-resident proteins could be introduced and retained within the scaffold’s
structure. Since the post cross-linked scaffolds absorbed more media than the +EDC
scaffolds, the increase in mass for these scaffolds could be attributed to the higher
absorption of media resulting in increased resident protein integration with the scaffolds.
The post dry mass increase observed in +EDC scaffolds containing HA may be attributed
to increased resident protein integration as well, considering that HA is a bioactive
nanofiller with the capability of increasing binding sites for proteins, minerals, and cells.
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Table 3.2 - Mass (mg) of dry scaffolds pre/post-incubation. * denotes post-culture mass is
statistically different (p<0.05) than pre-culture mass.
+EDC
Gelatin
+HA
+CW
+HA+CW
+PRGF
+PRGF+HA
+PRGF+CW
+PRGF+HA+CW

Pre
7.97 ± 0.57
12.17 ± 0.61
10.67 ± 0.98
11.20 ± 0.70
10.83 ± 0.99
11. 07 ± 0.45
9.63 ± 1.01
11.33 ± 0.65

Post
14.27 ± 1.51*
19.10 ± 0.78*
17.13 ± 9.29*
19.13 ± 8.39*
18.53 ± 1.60*
17.43 ± 0.47*
16.10 ± 0.27*
18.23 ± 0.40*

Pre
7.53 ± 1.40
8.17 ± 0.67
11.23 ± 0.95
7.23 ± 0.29
9.40 ± 0.53
8.13 ± 0.76
8.33 ± 0.50
8.10 ± 0.26

Post
6.20 ± 1.71
11.00 ± 1.31*
10.63 ± 1.45
7.93 ± 0.95
7.13 ± 0.81*
9.47 ± 0.21*
7.73 ± 0.31
9.47 ± 0.25*

3.4.2. Protein release
Original total protein content of all scaffolds was between 1500 and 2100 µg. The
+HA and +PRGF+HA scaffolds contained lower amounts of original protein when
compared to other +PRGF scaffolds while all other scaffolds were not statistically different
(p<0.05) from each other (Figure 3.3).
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Figure 3.3 - Original protein content of scaffolds. * denotes statistical differences
(p<0.05). The black and blue lines show statistical difference of +PRGF+HA and +HA,
respectively.

The protein release kinetics of different cross-linking methods and scaffold
compositions are compared over a 90 day incubation period and shown in Figure 3.4 A and
B. All +EDC scaffolds released higher amounts of protein after 1 day incubation than their
post-gelation cross-linked counterparts. The protein released from each +EDC scaffold
ranged between 40 and 185 µg while the post-gelation cross-linked scaffolds only released
a maximum of 35 µg. All +EDC scaffolds followed the same trend of protein release; a
high release on day 1, a steady decline throughout 14 days, a jump at day 21, then declined
to little/no release after 90 days. Throughout 56 days, the +EDC gelatin and +HA scaffolds
showed consistently higher and lower release, respectively. Post-gelation cross-linked
scaffolds had more variety in trends, however, the overall protein release remained low in
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comparison to the +EDC scaffolds. Graphs C and D in Figure 3.4 show the cumulative
protein released from scaffolds over 90 days. These graphs show the same trends as graphs
A and B; however, it provides a better perspective on overall protein release.

Figure 3.4 - (A & B) Protein release of scaffolds per time point. (C & D) cumulative
protein release over 90 days.

Total protein released from each scaffold after 90 days (Figure 3.4 C and D) was
compared to the original protein content of the scaffolds (Figure 3.3) to compute a
percentage of total protein released for each scaffold type after 90 days incubation. Table
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3.3 lists these percentages in descending order. The overall trend was that scaffolds crosslinked during gelation (+EDC) released more protein over 90 days than post-gelation
cross-linked scaffolds. These results indicate that the method of cross-linking has a
significant impact on the release kinetics of the scaffolds. In this study, where EDC
concentrations were identical between the two cross-linking methods (pre or post-gelation)
and the only difference was when the cross-linker was applied, it was apparent that the pregelation +EDC group were faster degrading than the post-gelation group. It is hypothesized
that the post EDC scaffolds degrade slower as a result of their stronger surface crosslinking since these scaffolds were submerged in an EDC solution. However, the +EDC
scaffolds were allowed to cross-link during gelation most likely resulting in more uniform
cross-linking throughout the interior of the scaffold. The lower amounts of cross-linking on
the surface could make the scaffold susceptible to faster degradation. While a quick rate of
degradation may not be ideal for a bone graft scaffolding material, it may be appropriate in
an orthopedic drug delivery scenario where a more rapid, yet still controlled release of
protein may be ideal. It should be noted that in this study, for the sake of simplicity, only a
single concentration of EDC was utilized. The ability to increase or decrease the
concentration of the EDC cross-linker allows users to truly tailor the rate of protein release
from the scaffold by effectively increasing or decreasing the degree to which the scaffold is
cross-linked.
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Table 3.3 - Percent total protein released after 90 days.

+PRGF+EDC
Gelatin+EDC
+PRGF+HA+EDC
+PRGF+HA+CW+EDC
+PRGF+CW+EDC
+HA+CW+EDC
+CW+EDC
+PRGF+HA
+HA+EDC
+PRGF
+PRGF+HA+CW
+HA
Gelatin
+PRGF+CW
+HA+CW
+CW

%
Released
27.79
19.30
19.18
16.75
15.62
13.94
13.66
9.29
8.61
6.59
5.32
4.95
3.43
2.98
1.68
1.23

3.4.3. Cell attachment, migration and matrix production
Scanning electron microscopy
Scaffold characterization, cell attachment, and matrix production was first analyzed
via scanning electron microscopy (Figures 3.5 and 3.6). Visually, all the acellular scaffolds
appeared similar in structure: a flaky surface with large pores. Differences were noticed
when observing MG-63 cell attachment after day 1. For post-gelation cross-linked
scaffolds, the addition of HA and any scaffold containing PRGF appeared to have more
cells attached (small dots in image). The same trend was observed for +EDC scaffolds with
the exception of +PRGF+HA+CW. As previously mentioned, PRGF contains cell adhesive
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proteins such as fibronectin and vitronectin. In addition, HA has the ability to adsorb these
and other cell adhesion proteins either from the serum once incubated or from the PRGF
pre-scaffold fabrication. The presence (in PRGF and serum) and/or adsorption (of HA) of
these cell adhesive proteins allow the scaffolds containing HA and/or PRGF to increase in
bioactivity and ultimately attach more cells, compared to the gelatin controls. After 28
days, little to no matrix was produced by the cells on the post-gelation cross-linked
scaffolds, however, the +HA, +HA+CW, +PRGF, and +PRGF+HA+CW +EDC scaffolds
showed mineral matrix production by the cells. After 90 days, cells on the post crosslinked scaffolds appeared to produce a more collagen bundle-like morphology matrix
rather than a bone-like mineral substance. Cells on +EDC scaffolds for 90 days appeared to
have produced more mineral matrix on the surface when compared to post cross-linked
scaffolds. By visual inspection of the SEM images, cells produced desired bone-like
mineral formation on the +HA, +HA+CW, +PRGF, and +PRGF+HA+CW +EDC scaffolds
suggesting these scaffolds to be conducive to bone formation.
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Figure 3.5 - SEM of post cross-linked scaffolds seeded with MG-63 cells for 1, 28, and 90
days. Magnification at 450x and scale bars at 50 µm.
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Figure 3.6 - SEM of +EDC cross-linked scaffolds seeded with MG-63 cells for 1, 28, and
90 days. Magnification at 450x and scale bars at 50 µm.
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Alizarin Red S staining
Absorbance was measured to compare the relative mineral content of the cellular
and acellular composite gelatin sponges incubated for 90 days (Figure 3.7). Each scaffold
composition was compared to itself at each day to determine if the addition of MG-63 cells
significantly increased or decreased (p<0.05) overall scaffold mineral content. Scaffolds
were only compared to themselves and not to other compositions since the initial amount
of mineral per scaffold varied (i.e. all scaffolds containing +HA had higher absorbance
values than scaffolds without +HA). For post cross-linked scaffolds, gelatin, +CW, and
+PRGF showed a significant decrease (p<0.05) in absorbance after 90 days with cells
when compared to 90 days without cells. The only post cross-linked scaffold that had a
significant increase (p<0.05) in mineral content as a result of cells was +PRGF +HA at day
28. For +EDC scaffolds, the addition of cells resulted in significant decreases (p<0.05) in
mineral content in gelatin (day 90), +PRGF (day 90), and +PRGF +CW (day 28 and 90)
scaffolds. However, there were more +EDC scaffolds that recorded higher absorbance
values as a result of the cells producing mineral matrix: +CW (day 28), +HA (day 28 and
90), +PRGF +HA (day 28 and 90), and +PRGF +CW +HA (day 28).
While the ARS results were not consistent for a specific group, the fact that a
number of groups exhibited statistically significant increases in mineral matrix production
was seen as a positive result indicative of the potential in vitro formation of new bone. The
statistically significant decreases between day 90 acellular scaffolds and day 90
cellularized scaffolds could be attributed to the previous mention of acellular scaffolds
continuously absorbing media (and in conjunction, resident proteins and calcium ions
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within the media) over 90 days. Alternatively, cells seeded on scaffolds remodel the
constructs as the cells migrate, proliferate, and produce matrix. The ARS stain may have a
higher affinity to these adherent resident proteins and calcium than a partially degraded
scaffold covered with cells, resulting in a higher ARS absorbance for acellular scaffolds. It
has been shown that Alizarin Red S has the ability to also bind to human serum albumin
(HSA) [124]. HSA is the most abundant protein in whole blood; as such it is present in
PRGF. In addition, bovine serum albumin is present in the cell culture media and can
potentially have binding affinity to ARS. In either instance there may be confounding
variables when using ARS on samples that have components of blood or that have been
exposed to culture media. Overall, the very nature of the ARS procedure (multiple
staining/de-staining and washing steps) makes it difficult to obtain truly accurate
quantifications of mineral production of cells on scaffolds. However, for the preliminary
nature of this study the ARS stain and its fairly positive results proved adequate in
demonstrating the osteoinductive potential of the modified gelatin sponges tested here.
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Figure 3.7 - ARS of acellular and cellular scaffolds over 90 days incubation. * denotes a
statistical difference (p<0.05) between cells and no cells for a specific day and scaffold
composition. # denotes a statistical difference (p<0.05) when comparing cross-linking
methods of each condition.
43

Statistical analysis was also performed between the two graphs to determine if
there were any significant differences in absorbance for a given scaffold on a particular
time point. A total of six post cross-linked scaffolds and five +EDC scaffolds showed
significant increases in absorbance values when compared to their cross-linked
counterparts (Table 3.4).

Table 3.4 - Scaffolds with significant increases (p<0.05) in absorbance values when
comparing cross-linking methods.

Day 1 cells
Day 28

post crosslinked
+PRGF +HA
+PRGF
+PRGF +HA

Day 28
cells
Day 90

+PRGF
+PRGF +HA

Day 90
cells

+EDC
+PRGF +CW

+CW
+HA
+PRGF +CW
+PRGF +HA
+CW

+PRGF

DAPI staining
The SEM images provided an overview of how cells attached and produced matrix
on the surface of gelatin composite sponges. Cell attachment and more importantly,
infiltration into the scaffold, was analyzed via DAPI staining. Not all images are reported
due to spatial constraints; however, the pure gelatin scaffolds (controls) are compared to
three other scaffold compositions that facilitated a more pronounced infiltration of cells. In
Figure 3.8, post cross-linked gelatin scaffolds are compared to +PRGF, +PRGF +HA, and
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+PRGF +HA +CW. After day 1, cells attached along the surface of the pure gelatin
scaffold while the other scaffolds promoted cell infiltration and attachment (as evidence of
blue cell nuclei visible throughout the cross section of the scaffold). With post crosslinked scaffolds, it appears that the addition of PRGF enhanced the attachment and
infiltration of cells when compared to the gelatin control. The milieu of growth factors and
cytokines contained within PRGF (some listed in Table 3.1) are known to be highly
chemotactic as well as have the ability to induce cellular attachment, proliferation, and
migration in a number of cell types. While the presence and release of PRGF derived
biomolecules was not specifically investigated in this study, it can be assumed that the
growth factors and cytokines contained within the PRGF are being eluted from the
scaffolds based upon previous studies conducted with the incorporation of PRGF into
electrospun scaffolds [87, 125]. These results suggest that these molecules remain active
post-scaffold fabrication and ultimately increase the bioactivity of the scaffolds.
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Figure 3.8 - DAPI staining of post cross-linked scaffolds with MG-63 cells for 1, 28, and
90 days. Images taken at 20x magnification.

Figure 3.9 compares the gelatin +EDC control to +CW, +PRGF, and +PRGF +CW
+EDC. A similar trend was noticed with the +EDC scaffolds in that cells attached mainly
to the control gelatin scaffold surface while the other scaffold compositions showed
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enhanced cell infiltration after day 1. However, it appears that more cells penetrated and
attached to +EDC scaffolds when compared to post cross-linked scaffolds. By day 28 and
90, it became increasingly difficult to distinguish fluoresced cell nuclei on any scaffolds,
independent of cross-linking methods. There appeared to be an abundance of newly
created cell matrix at days 28 and 90, especially with +EDC scaffolds. This newly
deposited matrix may have interfered with the staining, which commonly produced a
uniform fluoresced scaffold making it difficult to discern individual cell nuclei and analyze
day 28 and 90 DAPI images. With +EDC scaffolds, the addition of CW and/or PRGF
appeared to promote cell attachment and penetration when compared to the gelatin +EDC
control.
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Figure 3.9 - DAPI staining of +EDC cross-linked scaffolds with MG-63 cells for 1, 28,
and 90 days. Images taken at 20x magnification.
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3.4.4. Uniaxial compression testing
Peak load was recorded to determine the compressive strength of the cellular and
acellular composite gelatin sponges incubated for 90 days (Figure 3.10). Each scaffold
composition was compared to itself at each day to determine if the presence of cultured
cells strengthened or weakened the scaffold over the duration of culture. Most of the postgelation cross-linked scaffolds did not record a significant difference (p<0.05) between
cellularized and acellular scaffolds, meaning that the addition of cells did not significantly
affect the scaffolds compressive strength positively or negatively. However, significant
increases (p<0.05) in peak load as a result of culturing cells were observed for +PRGF
+HA +CW (day 1 and 28), +CW (day 28), and +PRGF +CW (day 28) post-gelation crosslinked scaffolds. Many of the scaffolds cross-linked during fabrication (+EDC) also did not
record significant differences (p<0.05) between cells and no cells when comparing
scaffolds to themselves at a specific day. Significant increases (p<0.05) in compressive
strength were recorded for +HA (day 28) and +CW +HA (day 28) scaffolds suggesting the
addition of cells improved scaffold strength.
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Figure 3.10 - Peak load (N) of acellular and cellular scaffolds over 90 days incubation.
*denotes a statistical difference (p<0.05) between cells and no cells for a specific day and
scaffold composition. # denotes a statistical difference (p<0.05) when comparing crosslinking methods of each condition.
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Upon comparing peak load between cross-linking methods, it was noticed that for
the majority of the scaffolds, the method of cross-linking had no significant effect (p<0.05)
on the compressive strength for a specific scaffold on a particular day. Cross-linking
during scaffold fabrication (+EDC) significantly increased (p<0.05) the compressive
strength of +HA (day 28 cells) and +CW +HA (day 28 cells) scaffolds. On the other hand,
+EDC scaffolds showed significant decreases in peak load for +PRGF +HA (day 28 no
cells), +PRGF +CW (day 28 cells), and +PRGF +HA +CW (day 1 cells) scaffolds.
While the nano-indentation for compressive mechanical properties produced
satisfactory results, future experiments will use a platen system for testing. Although the
nano indenter was within the appropriate size in diameter (2 mm) when compared to the
sample diameter (6 mm), there still remains the possibility of local variations in material
properties [126]. The platen system compresses the sample using two flat platens (larger
that the sample size) instead of a smaller indenter to measure mechanical properties.
3.5. CONCLUSION
In this study it was demonstrated that a lyophilized gelatin gel sponge, modified
through the addition of PRGF, HA, and CW, demonstrated clear osteogenic potential when
cultured with an MG-63 osteoblast-like cell line. These scaffolds, further modified through
EDC cross-linking during gelation, were able to remain intact after 90 days in culture
while exhibiting a controlled protein release. This tailorable rate of degradation is critical
in a bone repair scaffold, where scaffold breakdown needs to match the ingrowth of new
bony matrix to prevent catastrophic failure or the potential for micromotion or stress51

shielding to occur. While this preliminary study failed to determine a clear optimal
combination of gelatin and scaffold modifying agents (PRGF, HA, CW) to promote bone
regeneration, it demonstrated that the use of a lyophilized gelatin gel sponge with the
potential to absorb several times its weight in water was capable of eliciting cell infiltration
into the structures as well as promoting the formation of cell-created mineral matrix.
However, the +EDC scaffolds containing +PRGF+HA+CW performed well in the
preliminary evaluations and need to be further investigated going forward. Further testing
must be performed to more accurately determine the cellular interaction with these
scaffolds in particular the cellular response inside the structures.
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4. MINERALIZATION AND FURTHER CHARACTERIZATION OF
LYOPHILIZED GELTIN SPONGES ENHANCED WITH PRGF,
HA, AND CW

4.1. ABSTRACT
The application of freeze-dried gelatin sponges as alternative bone grafting
substitutes has many advantages which include ability to swell, high porosity, tailorable
degradation, and versatile ability to incorporate one or multiple components (proteins,
growth factors, inorganic nanofillers, etc.). The previous study demonstrated the enhanced
protein release and cell attachment/infiltration in scaffolds cross-linked during gelation
(+EDC) and in scaffolds incorporated with biological factors (HA, CW, and PRGF). The
purpose of this study was to further characterize freeze-dried gelatin sponges enhanced
with PRGF, HA, and CW and cross-linked during gelation (PHCE). Freeze-dried
gelatin+EDC (GE) scaffolds were used as a control. Scaffolds were also mineralized (M)
in 5x r-SBF to create a bone-like mineral surface. GE, GE-M, PHCE, and PHCE-M
scaffolds were characterized for their ability to swell, mineralization (ARS), surface
characteristics (SEM), protein release (BCA protein assay), release of PRGF, and uniaxial
compression properties (using 2 platens to record modulus and peak load). A growth factor
profile of PRGF was also obtained using a human angiogenesis kit and a multiplexer.
Growth factors detected in PRGF included VEGF-A, HGF, EGF, FGF-2, VEGF-C, IL-8,
and VEGF-D (listed in descending order of concentrations present). Both GE and PHCE
scaffolds were porous structures that swelled up to 50% of their original volume upon
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hydration. SEM showed sparse clusters of mineral deposition for GE-M scaffolds while
PHCE-M scaffolds exhibited a more uniform mineral deposition throughout the surface.
ARS was unable to detect any differences between mineralized and non-mineralized
scaffolds, however it did show a significant increase in mineral content between GE and
PHCE scaffolds which was expected since HA was incorporated within PHCE scaffolds
and not present in GE scaffolds. Over 21 days, scaffolds released more of their contents
during the first 7 days when compared to later time points. By day 21, PHCE-M scaffolds
cumulatively released about 30% of its original protein content, significantly more than all
other scaffolds. For uniaxial compression testing of hydrated sponges, PHCE-M scaffolds
report lower Young’s modulus values (1.3 - 1.6 MPa) when compared to GE and GE-M
scaffolds (1.6 – 3.2 MPa). These low modulus values are comparable to values of tissue
found in early stages of bone healing. The results of the study demonstrate the enhanced
performance of PHCE and PHCE-M scaffolds to serve as bone healing scaffolds. Their
potential to release incorporated factors and comparable composition and mechanical
properties to tissues developed in the early stages of bone healing make them suitable for
further studies evaluating cellular responses.
4.2. INTRODUCTION
There are several properties and characteristics to consider when fabricating an
ideal scaffold intended for bone tissue engineering. These include: biocompatibility,
degradability (as scaffold degrades, space is created for new bone), porosity (angiogenesis
and migration/infiltration of cells to deposit bone within), mechanical integrity (ability to
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maintain its structure and mimic mechanical properties found in bone healing
microenvironment),

osteoconductivity

(ability

to

support

bone

growth),

and

osteoinductivity (ability to differentiate osteoprogenitor cells into osteoblasts). A
lyophilized gelatin sponge cross-linked with EDC during gelation provides a
biocompatible, porous, and degradable scaffold. The addition of PRGF contains many
growth factors and cytokines which are known to enhance angiogenesis and osteogenesis
(as previously described). The incorporation of HA and CW is also known to enhance
osteoconductivity and mechanical integrity. The further acquisition of minerals to a
scaffold surface via SBF treatment can further enhance osteoconductivity of scaffolds. The
purpose of this study is to characterize acellular cross-linked lyophilized gelatin sponges
enhanced with PRGF, HA, and CW (PHCE). The addition of a bone-like mineral surface
from SBF treatment created mineralized (M) scaffolds which were also characterized and
compared to their non-mineralized counterparts. A growth factor profile of uncross-linked
PHC scaffolds and dilutions of PRGF, PRP, and PPP was obtained to identify key growth
factors present at different stages. Gelatin controls (GE) were compared to GE-M, PHCE,
and PHCE-M in regards to mineralization, protein release, growth factor incorporation, and
mechanical properties to determine if these scaffolds appropriately meet the design
characteristics of an ideal bone tissue engineering scaffold intended for early bone healing.
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4.3. MATERIALS AND METHODS

4.3.1. Fabrication of gelatin composite sponges
Based on the results from Chapter 3, the PRGF+HA+CW+EDC scaffolds exhibited
desirable characteristics of a potential bone tissue engineering scaffold and was further
studied in this experiment. Gelatin+EDC scaffolds served as the control. Lyophilized
gelatin+EDC (GE) and PRGF+HA+CW+EDC (PHCE) sponges were fabricated using the
same method as described in Chapter 3, Section 3.3.1. Briefly, a 30 mg/mL gelatin solution
in DI water was used as the base solution for creating gels. For GE scaffolds, 50 mM of
EDC was added to 4 mL of the gelatin solution, briefly mixed, pipetted into a 35 x 10 mm
Petri dish, and stored in a refrigerator at 4°C overnight to gel. For PHCE scaffolds, 3.33
mg/mL of both HA and CW were added to 4mL of the gelatin solution then sonicated. 3.33
mg/mL of PRGF was then added to the gelatin-HA-CW solution and allowed to
completely dissolve (about 3 mins). 50 mM EDC was then added to the 4 mL gelatinPRGF-HA-CW solution, briefly mixed, transferred to a 35 x 10 mm Petri dish, and
allowed to gel overnight at 4°C. After gelation of all solutions, gels were slowly frozen to
-70°C and lyophilized to obtain the composite porous sponges. 6 mm discs were then
punched and used for all studies.
4.3.2. Swelling percent
To quantify the initial swelling capability of the GE and PHCE lyophilized
sponges, measurements of the scaffold’s dimensions were recorded dry and after 1 day
hydration

in

DMEM

high

glucose

media
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containing

10%

FBS

and

1%

penicillin/streptomycin. Volume was calculated using the standard equation for the volume
of a cylinder (π * radius2 * height). The formula (hydrated volume – dry volume) / (dry
volume) was used to determine the swelling ratio of each scaffold. This ratio was then
multiplied by 100 to calculate the percent increase in volume for each scaffold as a result
of hydration (swelling percent).
4.3.3. Scaffold mineralization
The ionic concentrations of the commonly used SBF, conventional SBF (c-SBF),
are not exactly equal to those of blood plasma. Oyane et al. made revisions to c-SBF and
created three new SBFs (revised (r), ionic (i), and modified (m)) that have ionic
concentrations equal to, or closer to, those of blood plasma (Table 2.2). The ionic
concentrations of the r-, i-, and m-SBFs were formulated to equal those of total blood
plasma, dissociated blood plasma, and total blood plasma (except for HCO3-),
respectively. Of the compositions, r-SBF is the closest to the concentration of total blood
plasma; in fact it is an exact match. For this reason, a r-SBF solution was prepared by
following the published protocol for 1x r-SBF and increasing each ion concentration by a
factor of 5 [111]. A higher (5x) concentration of SBF was chosen in order to effectively
mineralize the scaffolds with minimal incubation time.
Triplicates of 6 mm (diameter) discs were punched from each of the composite
gelatin sponges and separately incubated in 1 mL of 5x r-SBF for 1 hour at 37°C and 5%
CO2 atmosphere. Preliminary studies mineralized scaffolds for 1, 6, and 12 hours and
determined that 1 hour incubation in 5x r-SBF was sufficient to mineralize the scaffold.
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Mineralization was performed under static conditions with the discs completely submerged
in SBF. After 1 hour incubation, scaffolds were removed and rinsed with DI water to wash
off any minerals that were not bound to the scaffold.

To visually inspect surface

mineralization, one scaffold disc was dehydrated and used for SEM analysis. For mineral
quantification, Alizarin Red S staining was used. GE and PHCE mineralized scaffolds are
denoted as GE-M and PHCE-M, respectively.
4.3.4. Scanning electron microscopy
Scanning electron microscopy (SEM) was performed in order to evaluate the
scaffold surface characteristics prior to and following mineralization. GE, GE-M, PHCE,
and PHCE-M samples were disinfected (30 minutes ethanol followed by three washes of
1x PBS) to simulate preparation for cell studies, air-dried, mounted on an aluminum stub,
carbon coated, and examined using a Hitachi SU-70 scanning electron microscope
(accelerating voltage at 20 kV).
4.3.5. Alizarin Red S staining
Alizarin Red S (ARS) staining was used to quantify scaffold mineral content by
modifying a published protocol as previously described in Chapter 3, Section 3.4.4. [112].
ARS was performed on the 6 mm scaffold punches before and directly after mineralization,
and after 21 days incubation in 1x PBS at 37°C and 5% CO 2. At the desired time points,
scaffolds were stained with 40 mM Alizarin Red for 30 minutes then washed with DI water
to remove any unbound stain. Scaffolds were then transferred to a 2 mL microcentrifuge
tube containing 1.5 mL of 50 % acetic acid to destain for 1 hour at room temperature. 500
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µL of the solubilized stain was added to 600 µL of 1 M NaOH to adjust the pH to 4.1. 200
µL of this solution was then pipetted into a 96-well plate and absorbance read at 550 nm
using a SpectraMax Plus 384 Microplate Spectrophotometer. Absorbance values were
compared to each other to determine any change in mineral content as a result of
mineralization or degradation.
4.3.6. Scaffold protein release
Release of protein from the scaffolds was measured as one parameter to assess
potential degradation. To determine total protein content of each 6 mm scaffold disc,
triplicates of non cross-linked 6 mm punch of each scaffold type were immersed in 1 mL
of 1x PBS. Non cross-linked scaffolds completely degraded within minutes at room
temperature, however scaffolds were left overnight to ensure complete degradation. Since
scaffolds are primarily comprised of gelatin, the degraded byproducts are detectable using
a general protein assay. Protein was quantified using a Pierce BCA Protein Assay as
previously described (in Chapter 3, Section 3.3.3.). Scaffold release kinetics were studied
by quantifying protein release from each scaffold over a period of 21 days. Triplicates of
one 6 mm disc of each cross-linked scaffold type were incubated in 1 mL of 1x PBS at
37°C with PBS replaced on every analysis point. After 1, 4, 7, 14, and 21 days the PBS
containing released scaffold contents in each well was analyzed for protein content using
the Pierce BCA Protein Assay.
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4.3.7. Growth factor analysis
The same protein release model described in Section 4.3.6 was used to identify and
quantify the PRGF growth factors incorporated and released from PRGF containing
scaffolds. After 1, 4, 7, 14, and 21 days the 1 mL of 1x PBS containing released PHCE and
PHCE-M scaffold contents in each well was analyzed for specific growth factor content.
As a control of total growth factors present in each scaffold, triplicates of 6mm discs of
uncross-linked gelatin+PRGF+HA+CW (PHC) scaffolds were completely degraded in
1mL of 1x PBS by overnight incubation at 37°C. Dilutions of pure PRGF (100, 50, 10, 1,
and 0.1 mg/mL), PRP (1:10 and 1:20), and platelet-poor plasma (PPP, 1:10, 1:20) in DI
water were also analyzed to obtain a profile of growth factors present in PRGF, PRP, and
PPP alone. This detection and quantification was accomplished by using a Luminex
MagPix multiplexer

(fluorescent

imager)

with the

MILLIPLEX® MAP

human

angiogenesis/growth factor magnetic bead panel 1. The Angiogenesis kit contained
analytes specific to detecting epidermal growth factor (EGF), granulocyte colonystimulating factor (G-CSF), fibroblast growth factor-1 (FGF-1), FGF-2, interleukin 8 (IL8), hepatocyte growth factor (HGF), vascular endothelial growth factor A (VEGF-A),
VEGF-C, and VEGF-D. The basic concept behind the Luminex technology is the use of
internally color-coded microspheres which are each coated with a specific capture antibody
(capable of capturing the analytes above). These microspheres are mixed with the released
contents of PHCE and PHCE-M scaffolds where the specific capture antibody can capture
the appropriate analyte. After this occurs, a biotinylated detection antibody is introduced
followed by the addition and incubation of a reporter/detection molecule to complete the
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reaction on the surface of each microsphere. Presence and quantification of analytes are
detected based on fluorescent reported signals read by the Magpix system.
4.3.8. Uniaxial compression testing
Uniaxial compression testing was performed on acellular 6 mm scaffold discs after 1, 4,
7, 14, and 21 days incubation in media. Mechanical testing was conducted by using 2 flat
metal platens from tension grips (in place of the indenter described in Chapter 3) attached
to a Bionix 200 Mechanical Testing System instrument with a 100 N load cell (MTS
Systems Corp., USA). The platen system was used to increase accuracy of compressive
mechanical testing by increasing the area of compression on the scaffold. The 2 platens
spanned the entire 6 mm scaffold disc, while the indenter was only 2 mm in diameter.
Platen compression was performed perpendicular to the scaffold surface without any
circumferential constraints to allow for free lateral deformation (Figure 4.1). Scaffolds
were removed from media, dabbed on a kimwipe to remove excess media/liquid, then
placed on the flat metal surface (samples were still hydrated). The upper platen was
lowered to the surface of the scaffolds and the following parameters were used: test speed
of 0.5 mm/min, data acquisition rate of 10 Hz, and a preload of 0.01 N. Compression was
continuous until the scaffold was completely flattened, the platens were compressing
against each other, and terminated just before the system maxed out at 100 N. Peak load
and Young’s modulus for compression were extracted and calculated using the graphical
output from the MTS software TestWorks 4.0. Peak load was extracted from the largest
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load value before the system began to max out. The compression modulus was calculated
using the initial linear region of the stress-strain curve [127].

Figure 4.1 - Compressive mechanical testing set up with scaffold between flat platens.
4.3.9. Statistical analysis
Statistical analysis was performed using JMP IN 9 statistical software (SAS Institute) to
determine significant differences. Analysis of the data was based on a Kruskal-Wallis oneway analysis of variance on ranks and a Tukey-Kramer pairwise multiple comparison
procedure. The results are presented in mean ± standard deviation (SD). Samples were run
at least in triplicates (n=3) to ensure statistical significance (p<0.05).
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4.4. RESULTS AND DISCUSSION

4.4.1. Swelling percent
In Chapter 3, it was discovered that these lyophilized gelatin composite sponges
have the ability to absorb the solution they are hydrated in (media and 1x PBS) and
significantly increase their mass. By calculating the swelling percent, we are able to further
characterize the hygroscopic nature of these sponges and their ability to potentially fill a
void space upon implantation. By calculating changes in volume, it was determined that
both GE and PHCE lyophilized sponges swelled approximately 50% (Figure 4.2). There
was no statistical difference (p < 0.05) between the swelling of GE and PHCE scaffolds
suggesting that the added components of PRGF, HA, and CW do not enhance nor hinder
the swelling ability of the scaffold. The result of no statistical differences in swelling could
be attributed to the fact that the 3.33 mg/mL of each PRGF, HA, and CW added to the 30
mg/mL gelatin solution was too low to overcome the natural sweling properties of the
gelatin sponge. It would be interesting to study the swelling percentage with increased
concentrations of PRGF, HA, and CW to determine if there is a threshold in which the
scaffold can no longer swell.

63

Figure 4.2 - Swelling percentage of GE and PHCE scaffolds upon hydration.
4.4.2. Scanning electron microscopy
Scanning electron microscopy (SEM) revealed surface characteristic differences
between GE and PHCE scaffolds, as well as mineralized and non-mineralized scaffolds
(Figure 4.3). GE scaffolds appear to have a smoother material surface with smaller pores
while PHCE scaffolds contain a rougher surface with larger pores. Since GE scaffolds are
only composed of gelatin, it is expected that they exhibit a more uniform surface
composition. The addition of growth factors and nanofillers for PHCE scaffolds alter the
scaffold characteristics by having a presence of the added molecules on the surface as well
as a larger pore size. It is hypothesized that the small spheres and rougher surface
visualized in Figure 4.3B is attributed to the incorporated nanofillers (HA and CW) present
on or near the surface of the scaffold. After mineralization, GE-M scaffolds showed small
clusters of mineral nucleation while PHCE-M scaffolds exhibited a more uniform
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attraction. One of the aims of this dissertation is to evaluate differences between
mineralized and non-mineralized scaffold protein release, mechanical properties, and
cellular response to understand any added benefit to the nucleation of crystals to the
scaffold surface.

Figure 4.3 - SEM of (A) GE, (B) PHCE, (C) GE-M, and (D) PHCE-M scaffold surfaces.
Scale bars at 100 µm.
4.4.3. Alizarin Red S staining
Alizarin Red S staining was performed on GE and PHCE scaffolds before and
directly after mineralization (Day 0). ARS was also performed on all scaffold types after
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21 days incubation in 1x PBS to asses any potential loss of mineral content as a result of
scaffold degradation (Figure 4.4). Results indicate a significant increase (p<0.05) in
mineral content between GE and PHCE scaffolds. This is expected since HA was
incorporated into the PHCE scaffolds and not within GE scaffolds. The ARS assay was not
sensitive enough to detect statistical differences between mineralized and non-mineralized
scaffolds. There were no significant differences (p<0.05) in absorbance values between all
scaffolds at day 21. In fact, all day 21 absorbance values (with the exception of GE-M)
were significantly lower (p<0.05) than day 0 values for the same scaffold type. This
suggests that some minerals are being released as the scaffold degrades. It is unclear as to
why the GE scaffolds had lower values at day 21 when compared to day 0. It was noticed
that ARS bound to GE scaffolds to some degree and is possible that this baseline affinity
binding was decreased as the scaffold degraded.

Figure 4.4 - ARS of GE and PHCE scaffolds directly before and after mineralization (Day
0) and of all scaffolds after 21 days incubation in 1x PBS.
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4.4.4. Scaffold protein release
One of the main considerations to take into account when designing any tissue
engineering scaffold is degradation. Scaffolds that degrade too quickly will fail early when
implanted, while extremely slow degrading scaffolds do not allow a favorable environment
for cells to remodel and replace the construct with new tissue. In this study, the Pierce
BCA assay was used to quantify amounts of general protein released from the lyophilized
composite gelatin sponges into solution. This data provides some insight into scaffold
degradation in that as the scaffold degrades, it releases its protein contents.
In order to understand the degree to which the scaffold is breaking down, we first
must know the original total protein content of the 6 mm discs. The original total protein of
each

disc

was

quantified

by

allowing

non

cross-linked

gelatin

(G)

and

gelatin+PRGF+HA+CW (PHC) scaffolds to fully degrade in PBS. There was no statistical
difference (p<0.05) between the average original total protein content of the G (1022 µg)
and PHC (1102 µg) scaffolds (Figure 4.5). It was expected that the PRGF containing
scaffolds would record higher initial protein values since it was an additive to the existing
gelatin solution. However, the small amounts of PRGF added (3.33 mg/mL) may not be
enough protein to record detectable differences when compared to the majority component
of gelatin (30 mg/mL). It is hypothesized that if a higher concentration of PRGF was added
to the scaffolds, then a detectable increase in protein content would be observed.
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Figure 4.5 - Original total protein content of non cross-linked scaffolds.

Knowing that the G and PHC scaffolds contain the same amount of total protein,
we can now directly compare GE, GE-M, PHCE, and PHCE-M release kinetics over 21
days without standardization. Figure 4.6A below graphically displays scaffold protein
release quantification over 21 days such that a comparison can be made between which
scaffolds released the most protein per time point. Interestingly, all scaffold types released
similar amounts of protein (no significant difference, p<0.05) on days 1, 7, and 14. On the
other hand, PHCE-M scaffolds released significantly more protein (p<0.05) on days 4 and
21 when compared to GE, GE-M, PHCE and GE, GE-M scaffolds, respectively. This data
suggests that PHCE-M scaffolds are degrading and releasing its contents at a faster rate
than all other scaffolds, particularly on days 4 and 21.
The same data presented in Figure 4.6A is graphed differently (Figure 4.6B) to
examine the protein release kinetics of a given scaffold composition over 21 days
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incubation in PBS. For GE scaffolds, there was a significant decrease (p<0.05) in release
on day 21 when compared to days 1, 4, and 14. However, a significant increase (p<0.05) in
release was observed between days 7 and 14. GE-M scaffolds exhibited a similar
significant decrease (p<0.05) in release on day 21 when compared to days 1, 4, and 7. Day
14 release from GE-M was also significantly lower than day 1. This suggests that most of
the release of GE-M scaffolds occurs within the first 7 days. For PHCE scaffolds, day 1
release was significantly higher (p<0.05) than all other time points. Day 4 PHCE release
was also significantly higher (p<0.05) than day 21. This data supports that there is a bulk
release of PHCE scaffolds on day 1, followed by sustained release of protein at lower
doses. For PHCE-M scaffolds, protein release on day 4 was significantly higher (p<0.05)
than on days 7, 14, and 21. These results suggest that for PHCE-M scaffolds, there is
normal release on day 1, while day 4 releases more compared to the following time points.
Overall, these results show that each scaffold has its own protein release profile which
indicates that mineralization can alter the scaffold degradation.
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Figure 4.6 - Comparison of protein released A) by scaffolds at a given time point and B)
over time, specific to each scaffold.

The protein release analysis presented up to this point focused on release kinetics of
a particular scaffold at a specific time point. However, the overall cumulative protein
release from each scaffold over the 21 days has yet to be discussed. Using the same data
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presented above, the cumulative protein release as a concentration and percent of total
protein released from each scaffold was summed and graphed (Figure 4.7). These graphs
illustrate that starting on day 4, PHCE-M release more protein overall compared to all
other scaffold types. Specifically looking at Figure 4.7B, we are able to demonstrate that
PHCE-M scaffolds are releasing 5% of its total protein content between days 14 and 21
while all other scaffold types are only releasing approximately 1%. This suggests that
PHCE-M scaffolds are capable of sustained release of high quantities of protein even at
later time points.
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Figure 4.7 - Cumulative protein release measured as A) concentration and B) percent of
total protein from scaffolds over 21 days.

In order to gain a relative understanding of protein quantity released by each
scaffold, day 21 cumulative released amounts were compared to non cross-linked original
total protein content to determine the percentage of protein released (Figure 4.8). GE, GEM, PHCE, and PHCE-M released 19.5%, 21.4%, 16.9%, 30.7%, respectively. Cumulative
protein release from PHCE-M scaffolds was significantly higher (p<0.05) than all other
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scaffolds. GE-M cumulative release was also significantly higher (p<0.05) than only
PHCE release. These results show that PHCE-M scaffolds are capable of 30.7% release of
its incorporated protein within the first 21 days and that mineralization of PHCE scaffolds
increases protein release. The increase in mineralized scaffold protein release could be
attributed to the gaps that form during mineralization between the inorganic particles and
the polymer matrix which can provide channels for the penetration of water [128].
Continuous elevated sustained release of protein is ideal for tissue engineering scaffolds,
rendering PHCE-M scaffolds a viable candidate for tissue regeneration constructs.

Figure 4.8 - Cumulative protein released (after 21 days) as a percentage of the original
total protein content.
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4.4.5. Growth factor analysis
Understanding which growth factors are present in liquid PRP and PRGF
(lyophilized PRP) are important when analyzing cellular responses to scaffolds. Although
PPP was not used in this study, a growth factor analysis of PPP was performed to
understand the composition and difference between PRP and PPP. In this study, a PRGF,
PRP, and PPP growth factor profile curve was obtained from dilutions of pure PRGF (100,
50, 10, 1, and 0.1 mg/mL), PRP (1:10 and 1:20), and PPP (1:10 and 1:20) in DI water.
Although these profiles do not encompass all growth factors present in PRGF, PRP, and
PPP, it does provide an analysis of the several key factors (Figure 4.9). Of the analytes
used, only two growth factors (G-CSF and FGF-1) were not detected and therefore not
present in PRGF, PRP, or PPP. The highest concentrations of growth factors detected in
PRGF and PRP were HGF and VEGF-A. Lower amounts of EGF, FGF-2, and VEGF-C
were also present. IL-8 and VEGF-D were detected at even lower concentrations. As
expected, the dilutions of PRGF and PRP resulted in low recorded values for all growth
factors. However, PRGF (100 and 50 mg/mL) and PRP (1:10 and 1:20) provide a strong
profile of growth factors present. It was expected that PRGF and PRP report the same
growth factor profile since PRGF is a lyophilized version of PRP. This demonstrates that
of the factors analyzed, PRP lyophilization does not affect the growth factors present in
PRGF. It was noticed that the concentrations for each growth factor within PRP (1:10 and
1:20) more closely resemble the PRGF values at 10 mg/mL dilution. Since PRP is a liquid,
it is measured in volume when administered clinically and experimentally. Alternatively,
PRGF is measured as a weight/volume concentration since it is a powdered substance. This
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analysis suggests that the concentrations of growth factors present in a 1:10 and 1:20
dilution of PRP is comparable that found in 10 mg/mL of PRGF. Table 4.1 presents the
mean value of all growth factor concentrations within PRGF, PRP, and PPP dilutions with
PRP (1:10 and 1:20) and PRGF (10 mg/mL) highlighted to show the comparison of similar
growth factor concentrations. As summarized in Chapter 2 and table 2.1, PRGF
components have positive effects on angiogenesis and bone remodeling both in vivo and in
vitro. PPP was not expected to contain high concentrations of growth factors since there
are a low number of platelets. The analysis of PPP dilutions revealed the low presence of
FGF-2, HGF, VEGF-A, VEGF-C, and VEGF-D. The growth factor profile of PPP (1:10)
more closely resembles that of PRGF (1 and 0.1 mg/mL), both highly diluted solutions.
The PPP growth factor analysis profile is also presented in Table 4.1.

75

Figure 4.9 - Growth factor analysis of (A) PRGF, (B) PRP and PPP dilutions.
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Table 4.1 - Average growth factor concentration (pg/mL) in PRGF, PRP, and PPP
dilutions. The average of the lowest standard is presented as the minimum level of
detection (Min Detection).

PRGF100
PRGF50
PRGF10
PRGF1
PRGF0.1
PRP 1:10
PRP 1:20
PPP 1:10
PPP 1:20
PHC
Min Detection

EGF
FGF-2 IL-8
HGF
VEGF-A VEGF-C VEGF-D
121.0
93.6 20.5 700.2
970.8
48.1
13.8
105.3
78.0 19.3 569.2
789.8
51.9
25.6
28.9
12.6
3.9 124.3
105.6
25.6
7.2
0.0
9.0
0.2
12.2
4.4
1.2
0.0
0.0
9.0
0.0
1.1
0.0
0.0
0.0
57.3
22.8
4.9 135.8
156.4
30.1
1.0
42.4
15.7
3.2 100.4
99.3
22.7
0.9
0.0
8.3
0.0
12.7
0.0
1.5
0.8
0.0
8.1
0.0
8.9
0.8
0.4
0.1
13.9
10.1
0.0
4.3
9.4
2.4
0.2
2.7
13.7
1.4
27.2
13.7
6.8
6.9

Multiplexer analysis of the uncross-linked PHC scaffolds provides the growth
factor profile of the original content of each scaffold. There were detectable amounts of all
growth factors in PHC scaffolds with concentrations ranging between PRGF 10 mg/mL
and PRGF 1 mg/mL (Table 4.1). The reported concentrations of growth factors are
expected since 3.33 mg/mL PRGF was used to fabricate PHCE scaffolds. These results
confirm that PRGF can successfully be incorporated within lyophilized gelatin sponges
and the presence/concentrations of growth factors (specifically EGF) are maintained.
Multiplexer analysis of PHCE and PHCE-M scaffold release over 21 days showed no
quantifiable traces of the above growth factors. It was expected that some growth factors
would be detectable as the scaffold degraded and released its contents. This absence of
measurable growth factors from scaffold release could be a result of a highly diluted
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sample since 6 mm discs were incubated in 1 mL of PBS to assess degradation. In this
instance, growth factors released from the scaffold become diluted in the high volume of
PBS which may result in no detection (as evident of the dilutions of pure PRGF in Figure
4.9). It is also possible that there was not enough PRGF originally incorporated within the
PHCE scaffolds such that any release is in small amounts and therefore not detected by the
multiplexer. On the other hand, it could be stated that there is no detectable growth factors
in the release because PRGF is simply not being released. This non-release of PRGF can
potentially be an added benefit in that the scaffold is able to maintain the incorporated
growth factors and constantly provide a bioactive surface for cells to attach, proliferate,
and remodel. Future studies will focus on which of these situations is occurring with
lyophilized gelatin/PRGF sponges. This will be conducted by degrading the scaffold in less
solution (to remove the possibility of severe dilution) and by incorporating higher initial
concentrations of PRGF.
4.4.6. Uniaxial compression testing
Uniaxial compression testing using a platen system was used to record peak load
(N) and Young’s modulus (MPa) for compression of scaffolds incubated in media for up to
21 days. Day 4 of mechanical testing was not reported as the mechanical properties
showed more significant changes weekly. Figure 4.10A reports and analyzes the peak
loads of each scaffold type at a given time point. At days 1 and 14, GE-M scaffolds
exhibited significantly higher (p<0.05) peak loads than all other scaffolds. On days 7 and
21, GE and GE-M had significantly higher (p<0.05) peak values than PHCE and PHCE-M
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scaffolds. This data suggests that throughout 21 days, PHCE and PHCE-M scaffolds
consistently report significantly lower (p<0.05) peak load values (0.1 – 1.0 N) when
compared to GE and GE-M scaffolds (1.0 – 2.7 N).
The same data was graphed differently to compare peak values of a given scaffold
throughout 21 days incubation (Figure 4.10B). For GE scaffolds, day 1 and day 14
produced the significantly lowest and highest (p<0.05) values, respectively. For GE-M
scaffolds, incubation for 14 days in media produced the highest (p<0.05) peak load value
compared to all other days. Day 1 for PHCE scaffolds was significantly lower (p<0.05)
than all other days while PHCE-M scaffolds showed no significant changes (p<0.05) in
peak load throughout 21 days. With the exception of PHCE-M scaffolds, this data shows
that scaffolds have lower peak loads at earlier time points (days 1 and 7) when compared to
later time points (day 14).
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Figure 4.10 - Peak load of scaffolds A) at a given time point and B) over 21 days
incubation in media.
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Figure 4.11A reports and analyzes the compressive modulus of each scaffold type
at a given time point. After 1 day incubation, PHCE-M scaffolds had a significantly lower
(p<0.05) modulus than all other scaffold types. In fact, GE scaffolds had significantly
higher (p<0.05) values than GE-M and PHCE-M. For day 7, GE scaffolds reported a
significantly higher (p<0.05) modulus than both PHCE and PHCE-M scaffolds. After 14
days incubation, GE and GE-M scaffolds had significantly higher moduli when compared
to PHCE-M scaffolds. Day 14 shows a higher modulus for GE-M scaffolds when
compared to GE and PHCE-M scaffolds. Overall PHCE-M scaffolds report lower Young’s
modulus values (1.3 - 1.6 MPa) when compared to GE and GE-M scaffolds (1.6 - 3.2
MPa). One aim of this study is to create a scaffold with similar mechanical properties to
that of native bone healing tissue. The first stages of bone healing involve granulation
tissue and hyaline cartilage (soft tissue) formation before any mineralization occurs. The
Young’s modulus of cartilage in the literature is at similar low values of 0.5-0.8 MPa while
mature bone and other materials are in the GPa range [129]. Zhang et al. report similar
low compressive Young’s modulus values (0.3 – 3.0 MPa) for gelatin-hyaluronic acid
composite freeze-dried sponges intended for soft tissue engineering applications [127]. The
low range of modulus values of these scaffolds provide a mechanical microenvironment
similar to that found in the early stages of bone healing.
Evaluating statistical differences in Young’s modulus of a given scaffold over 21
days will provide a different viewpoint on how each scaffold’s properties change over
time. To achieve this, the same modulus data was graphed with the legend and x-axis
switched and statistics were performed (Figure 4.11B). The modulus for GE and PHCE
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scaffolds significantly decreased (p<0.05) after 21 days incubation in media while their
mineralized counterparts showed no significant changes (p<0.05) in modulus within the
same time period. This suggests that mineralized scaffolds maintain their modulus
throughout incubation while non-mineralized scaffolds show a decrease. It is also noticed
from Figure 4.11A that the initial modulus (Day 1) of mineralized scaffolds is significantly
lower (p<0.05) than non-mineralized scaffolds. This could attribute to the decrease in
modulus as seen in non-mineralized scaffolds since they start off at higher values.
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Figure 4.11 - Young’s modulus for compression of A) scaffolds at a given time point and
B) a given scaffold over 21 days incubation in media.
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4.5. CONCLUSION
Lyophilized gelatin sponges were enhanced with PRGF, HA, and CW and crosslinked during gelation. Both control GE scaffolds and PHCE scaffolds swelled 50% their
original size upon hydration. After fabrication, scaffolds were subsequently mineralized to
create a bone-like surface. GE scaffolds nucleated minerals in more of a sparse aggregate
manner while PHCE scaffolds showed more uniform mineralization across the surface.
The highest concentrations of growth factors detected in PRGF and PRP were HGF and
VEGF-A. As presented in Table 2.1, VEGF and HGF are known to increase angiogenesis,
osteoblast proliferation, and endochondral ossification which are all vital to bone
regeneration. The growth factor profile of PPP (1:10) more closely resembled that of
PRGF (1 and 0.1 mg/mL), both highly diluted solutions. The BCA protein assay showed
that PHCE-M scaffolds degraded faster and released 30% of its original protein content.
Although PHCE-M scaffolds degraded the fastest, no PRGF growth factors were
detectable after analyzing contents of released protein. However, multiplexer analysis did
reveal the successful incorporation of PRGF within uncross-linked PHC sponges. The
lower compression moduli values of PHCE and PCHE-M scaffolds are comparable to
moduli values of tissues found in the early stages of bone healing. These findings suggest
that PHCE and PHCE-M scaffolds have potential for use as early bone healing tissue
scaffolds; however, in vitro cellularized studies are required to assess cellular responses to
the various composite porous sponges.
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5. IN VITRO RESPONSE OF MG-63 OSTEOBLAST-LIKE CELLS
CULTURED ON LYOPHILIZED GEALTIN SPONGES
ENHANCED WITH PRGF, HA, CW, AND A BONE-LIKE
MINERAL SURFACE
5.1. ABSTRACT
The development of three-dimensional porous scaffolds with enhanced osteogenic
and angiogenic factors are important characteristics to consider when fabricating scaffolds
intended for bone tissue engineering, specifically early bone healing. The previous study
demonstrated the advantages of PHCE and PHCE-M scaffolds which included: swelling
potential, successful incorporation of growth factors, controlled release properties, and
similar compression moduli as tissues present in early bone healing. In this study, GE, GEM, PHCE, and PHCE-M scaffolds were dynamically seeded with MG-63 osteoblast like
cells for 21 days and cellular responses to scaffolds as well as scaffolds response to cells
were evaluated. Specifically, cell proliferation, attachment, infiltration, protein/cytokine
secretion (osteocalcin, osteopontin, IL-6, IL-1β, TNF-α), and scaffold compressive
mechanical properties (peak load and modulus) were evaluated. Scaffolds were crosslinked with EDC, a potentially cytotoxic carbodiimide. As such, a basic cytotoxicity
experiment was performed to determine if uncross-linked EDC is harmful to the cells.
Results indicated that uncross-linked EDC in media at any concentration (from 0.8 – 50
mM) is cytotoxic to MG-63 cells. Since cells on scaffolds were viable for up to 21 days in
this study and up to 90 days in Chapter 3, it was concluded that there is no residual harmful
uncross-linked EDC which will negatively affect cell response. Both DAPI staining and
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MTS cell proliferation assay reported increased proliferation of cells on GE-M and PHCE
scaffolds, and decreased proliferation on PHCE-M scaffolds. DAPI imaging showed a
noticeable increase in initial cell attachment and infiltration of PHCE and PHCE-M
scaffolds on day 1. GE-M scaffolds also attached more cells than the GE control. MTS
results indicated that PHCE scaffolds increased cell proliferation after 4 and 7 days when
compared to GE controls. It also showed that the addition of a mineral coating to GE
scaffolds increases cell proliferation at day 4. Analysis of MG-63 protein/cytokine
secretion suggests that the cells are responding in a bone regenerative fashion when seeded
on all scaffolds, as evidence of osteocalcin secretion. Little to no secretion of osteopontin,
IL-1β, and TNF-α demonstrates that scaffolds are not influencing cells to secrete factors
associated with bone resorption. Cells also secreted small amounts of IL-6 when seeded on
scaffolds for 1 day. IL-6 is a cytokine known to have both bone regenerating and resorbing
effects. The compressive mechanical properties of cellularized scaffolds did not differ
much from acellular scaffolds. There were a few exceptions where cells remodeled the
scaffold such that increased peak load (PHCE, PHCE-M, GE-M day 14) and modulus (GE
and PHCE day 21) were recorded. The combined results increased cellular attachment,
infiltration, and bone regenerative protein/cytokine secretion by cells on GE-M scaffolds
support the addition of a bone-like mineral surface to GE scaffolds. Cellularized PHCE
and PHCE-M scaffolds report similar advantages as well as Young’s modulus values in the
range of native tissues present in the early stages of bone healing. These results suggested
that the developed PHCE and PHCE-M scaffolds exhibit good cellular response and
mechanical properties for early bone healing applications.
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5.2. INTRODUCTION
As previously mentioned, designing scaffolds intended for bone tissue engineering
must satisfy certain criteria such as: biocompatibility, degradability, porosity, mechanical
integrity, osteoconductivity, and osteoinductivity. Chapter 3 illustrated that porous
lyophilized gelatin sponges enhanced with PRGF, HA, and CW, allow the attachment
(bioactivity), infiltration (porosity), and secretion of bone-like matrix (osteoconductivity)
after static culture with MG-63 osteoblast-like cells. Chapter 4 further analyzed and
reported positive results for protein release, mechanical integrity, and the ability to
incorporate osteogenic factors within mineralized and non-mineralized PHCE scaffolds.
The aim of this study is to analyze the cellular response of MG-63 cells dynamically
seeded on GE, GE-M, PHCE, and PHCE-M scaffolds. The motive for dynamic cell
seeding was to provide an environment where cells are not “forced” onto the scaffold (as
seen in static cell seeding). In this seeding technique, the scaffolds were floating in a cell
suspension in a rotary cell culture system (bioreactor) where they can come in contact with
each other and if the scaffold is bioactive, it will promote cell attachment and infiltration.
Since scaffolds are mineralized and/or incorporated with a variety of growth factors, it is
hypothesized that cells will proliferate and secrete proteins/cytokines differently on various
scaffolds. Osteocalcin and osteopontin are the main proteins secreted by osteoblasts
indicative of bone regenerative and bone resorptive behavior, respectively. In addition to
detecting osteocalcin and osteopontin, the secretion of other bone regenerating (IL-6) and
resorbing factors (IL-6, IL-β, and TNF-α) were recorded. IL-6 is a controversial cytokine
in that it is has been found to be associated with both bone resorption and regeneration
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(Table 5.1). This study also compares acellular and cellular mechanical properties to
determine what affect, if any, cells will have on the peak load and modulus of lyophilized
sponges.
5.3. MATERIALS AND METHODS

5.3.1. Fabrication of gelatin composite sponges
Gelatin+EDC (GE) and PRGF+HA+CW+EDC (PHCE) lyophilized sponges were
fabricated and subsequently mineralized (GE-M and PHCE-M) as previously outlined in
Chapter 4, Sections 4.3.1 and 4.3.3. For all in vitro cell studies, MG-63 cells (human
osteoblast-like cells derived from an osteosarcoma) were used. MG-63 cells behave similar
to osteoblasts with their attachment, migration, proliferation, and bone matrix production.
5.3.2. Cytotoxicity of uncross-linked EDC
To determine the cytotoxic effect of potential residual uncross-linked EDC, a cell
proliferation assay was performed and cells were exposed to various concentrations of
uncross-linked EDC. Briefly, MG-63 cells were seeded subconfluently in a 96-well plate at
5,000 cells/well in 100 µL of control media (DMEM high glucose, 10% fetal bovine
serum, 1% penicillin/streptomycin). Following the adhesion of cells to the well plate
(approximately 1 hour), control media was removed and replaced with conditioned media
(control media supplemented with 0, 0.8, 1.5, 3.1, 6.3, 12.5, 25, and 50 mM EDC). An
MTS assay (Cell-Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay, Promega,
Madison,WI, USA) was performed on days 1, 4, and 7 (with media changes on days 1 and
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4) to determine mean proliferative cell count. At the termination of each time point,
conditioned media in each well was removed and replaced with 100 µL of control media
and MTS was performed per manufacture’s protocol.
5.3.3. Cell seeding on scaffolds
In Chapter 3, MG-63 cells were statically seeded on 6 mm-sized scaffold discs in a
96-well plate. Although the static method produced sufficient preliminary results, a more
in vivo-mimicking method is appropriate for cell seeding. For this experiment, a dynamic
(floating scaffold) cell seeding technique was used to not “force” the cells to attach to the
scaffold. To accomplish this, a rotary cell culture system (Synthecon, Inc.) was used. Four
bioreactors (60 mL volume capacity each) were autoclaved and attached to the rotary
system in a sterile incubator for dynamic cell seeding. Twelve 6 mm discs of each scaffold
type (GE, GE-M, PHCE, PHCE-M) were disinfected (30 mins ethanol followed by three
10 min washes in 1x PBS) and transferred to separate bioreactors. MG-63 osteoblast-like
cells were suspended in control media at a concentration of 50,000 cells/mL. 60 mL of this
cell solution was then added to each bioreactor containing disinfected scaffolds.
Bioreactors with scaffolds floating in cell suspension were placed in an incubator with
standard culture conditions (37°C and 5% CO2) and turned on (42 rpm) to allow
circulation of cell suspension solution and tumbling of floating scaffolds. After dynamic
cell seeding for 6 hours, scaffolds were then transferred from the bioreactor to a 96-well
plate containing 150 µL of culture media and statically cultured for 1, 4, 7, 14, 21 days
with media changes every 3 days. Cellular scaffolds were characterized for attachment,
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proliferation, infiltration, secretion of osteogenic factors, and compressive mechanical
properties.
5.3.4. Scanning electron microscopy
After 1, 4, 7, 14, and 21 days in culture, cellularized scaffolds were fixed in 1 mL
of 10% formalin and stored at 4°C until further analysis. Prior to imaging, cellularized
scaffolds were removed from formalin, briefly rinsed in PBS and DI water, subjected to
ethanol dehydration (10 minute soaks in 30, 50, 70, 90, and 100 % ethanol, subsequently),
and air dried overnight. All dry samples were mounted on aluminum stubs, sputter coated
in gold for 70 seconds, and examined using a JEOL JSM-5610LV scanning electron
microscope (accelerating voltage at 20 kV).
5.3.5. Cell attachment and proliferation
After dynamic MG-63 cell seeding, GE, GE-M, PHCE, and PHCE-M scaffolds
were cultured for 1, 4, and 7 days in a 96-well plate with 175 µL of control media with
media changes on days 1 and 4. The MTS cell proliferation assay mentioned in Section
5.3.2 was also used to determine proliferative cell count on scaffolds. After each time
period, scaffolds were transferred to a new well containing 100 µL of control media. 20 µL
of MTS+PMS solution was then added to the well containing the media plus scaffold and
incubated for 1 hour at 37°C. 100 µL of this solution was then transferred to a new 96-well
plate and absorbance read at 490 nm.
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5.3.6. DAPI staining
GE, GE-M, PHCE, and PHCE-M scaffolds were dynamically seeded with MG-63
cells as described in Section 5.3.3. After 1, 4, 7, 14, and 21 days in culture, cellularized
scaffolds were fixed in 1 mL of 10% formalin and stored at 4°C until further analysis.
Scaffolds were prepared for DAPI staining as mentioned in Chapter 3, Section 3.3.4.
Briefly, scaffolds were removed from formalin, immersed in sucrose solution 48 hours at
4°C, suspended in frozen sectioning compound, and frozen at -70°C overnight. 60 µm
slices were cryosectioned and transferred to microscope slides. Sample cross-sections were
then stained with 4’-6-diamidino-2-phenylindole (DAPI) stain for 5 minutes and imaged
using a UV fluorescent microscope to display the location of cell nuclei. As previously
discovered, the ability to image cells via DAPI staining becomes increasingly difficult after
weeks of culture. Therefore, only days 1 and 4 DAPI images are reported and serve as an
indication to initial cell attachment and infiltration.
5.3.7. Multiplexer analysis of secreted osteoblast factors
GE, GE-M, PHCE, and PHCE-M scaffolds were dynamically seeded with MG-63
cells and statically cultured for 1, 4, 7, 14, and 21 days. At each time point, media from
each well was collected and analyzed for osteoblast secretion of osteocalcin, osteopontin,
interleukin -1 beta (IL-1β), IL-6, and tumor necrosis factor-alpha (TNF-α). This detection
and quantification was accomplished by using a Luminex MagPix multiplexer (fluorescent
imager) with the MILLIPLEX® MAP Human Bone Magnetic Bead panel (containing the
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above mentioned analytes). This technology is the same as described in Chapter 4, Section
4.3.7.
5.3.8. Uniaxial compression testing
After 1, 4, 7, 14, and 21 days culture in media, cellularized scaffolds (6 mm diameter)
of each scaffold type were subjected to compressive mechanical testing (as described
Chapter 3, Section 3.3.5). Briefly, mechanical testing was conducted by using 2 flat metal
platens and performed perpendicular to the scaffold surface without any circumferential
constraints to allow for free lateral deformation. Scaffolds were removed from culture
media, dabbed on a kimwipe to remove excess media/liquid, then placed on the flat metal
surface (samples were still hydrated). Compression was performed as described in Chapter
4, Section 4.3.8. Peak load (N) and Young’s modulus (MPa) were extracted and calculated
using the graphical output from the MTS software TestWorks 4.0.
5.3.9. Statistical analysis
Statistical analysis was performed using JMP IN 9 statistical software (SAS Institute) to
determine significant differences. Analysis of the data was based on a Kruskal-Wallis oneway analysis of variance on ranks and a Tukey-Kramer pairwise multiple comparison
procedure. The results are presented in mean ± standard deviation (SD). Samples were run
at least in triplicates (n=3) to ensure statistical significance (p<0.05).
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5.4. RESULTS AND DISCUSSION

5.4.1. Cytotoxicity of uncross-linked EDC
EDC is a commonly used carbodiimide that has proven successful for cross-linking
scaffolds while maintaining bioactivity [127, 130-132]. However, the MG-63 cellular
response to potential exposure to any amount of uncross-linked EDC has not been
determined. Figure 5.1 reports the MTS cell proliferation assay results of varying
concentrations of EDC in media directly exposed to cells. It was determined that uncrosslinked EDC in any concentration (from 0.8 – 50 mM) is cytotoxic to MG-63 cells. This is
an important finding because any residual uncross-linked EDC present on or within the
scaffold will cause the cells to die. As shown in Chapter 3 and later in this chapter, cells
remain viable on all EDC cross-linked sponges for up to 90 days, suggesting there is no
uncross-linked residual cytotoxic EDC that is harmful to the cells. For the control well
(EDC 0 mM) there is a significant increase in cell proliferation from day 1 to 4 followed
by a significant decrease in proliferation from days 4 to 7. Since MTS is commonly used as
a cell viability assay, by quick glance of these results, one may conclude that cells began to
die after 4 days of culture. However, by visual inspection of all the wells (conditioned and
control), it was apparent that cells exposed to any concentration of EDC were in fact dying
(cells balled up and floating). Cells in the control wells on day 4 and 7 were very
confluent. The decrease in the MTS reading of 0 mM EDC on day 7 could be attributed to
the decrease in the number of proliferating cells. As cells become confluent in the well
plate (day 4), they stop proliferating and begin preparing to secrete factors conducive to
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bone remodeling. Although both day 4 and 7 wells had a confluent layer of cells, day 7
recorded a lower number of proliferating cells suggesting cells are not dying, but rather
progressing to the next stage of secreting factors for bone remodeling. Analysis of media
for bone remodeling markers is one method to confirm this hypothesis.

Figure 5.1 - MTS cell proliferation assay with varying concentrations of EDC in media.

5.4.2. Scanning electron microscopy
Scanning electron microscopy was performed on GE, GE-M, PHCE, and PHCE-M
scaffolds after dynamic cell seeding and subsequent static culture for 1, 4, 7, 14, and 21
days (Figures 5.2 and 5.3). Scaffolds were subjected to ethanol dehydration in order to
image cellularized scaffolds. Ethanol dehydration is a procedure commonly used to prepare
cellular scaffolds for imaging. However, since these sponges are hygroscopic in nature,
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dehydration caused the scaffolds to shrink upon preparation for imaging. Therefore, the
images presented here and in Chapter 3 are not representative of a fully hydrated swollen
scaffold that cells are in contact with. Although this is the case, basic observations can still
be made. One noticeable difference with the images presented in this chapter is the visual
appearance of no cells attached to any scaffolds at any time point. In Chapter 3, cells
attached more as spheres and were easily visualized via SEM. Later in the chapter, DAPI
staining confirms the presence of cells on and within GE, GE-M, PHCE, and PHCE-M
scaffolds. It is plausible that the dynamic cell seeding technique caused the cells to attach
to and integrate with the scaffold better than static cell seeding (where spheres of cells
were visualized). It is also possible that there are more cells within the scaffold rather than
on the surface, in which case will not be captured via SEM. Since mechanical stress is a
factor for bone development, it has been shown that osteoblasts respond differently to
mechanical stimuli when compared to a static environment [133, 134]. Future studies
could focus on the degree of cell attachment and infiltration into the scaffold under
dynamic and static culture conditions. For GE, GE-M, PHCE, and PHCE-M scaffolds, it
was also observed that the scaffold became less porous over 21 days. This could be due to
the remodeling of the scaffold by the cells, however, more in depth cell experiments
analyzing the surface and entire cellular scaffold will need to be conducted for any
conclusive results.
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Figure 5.2 - SEM of cellularized GE and GE-M scaffolds. Scale bars at 50 µm.
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Figure 5.3 - SEM of cellularized PHCE and PHCE-M scaffolds. Scale bars at 100 µm.
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5.4.3. Cell attachment and proliferation
The MTS assay was again used to determine the proliferative nature of cells
dynamically seeded and subsequently statically cultured on scaffolds. MTS was also
performed on acellular scaffolds of each type to determine any background or baseline
values. As expected, MTS values for all acellular scaffolds ranged from 0 to 90 cells,
indicating that there is no significant background or baseline value as a result of the MTS
solution interacting with the acellular scaffold. Figure 5.4A reports the MTS values of
cellularized scaffolds at a given time point. For day 1, there was no significant difference
(p<0.05) in cell proliferation between all scaffold types. On day 4, both GE-M and PHCE
scaffolds reported a significantly higher count of proliferative cells compared to GE and
PHCE-M. Day 4 results offer contradicting effects of mineralization on GE and PHCE
scaffolds. On day 4, a mineralized GE scaffold increases cellular proliferation when
compared to a non-mineralized GE scaffold. The opposite effect is observed for PHCE
scaffolds where a non-mineralized PHCE scaffold reports a higher cell proliferation count
compared to its mineralized counterpart. By day 7, there was no detection of proliferating
cells on PHCE-M scaffolds, while PHCE scaffolds showed increased proliferation when
compared to the GE scaffolds. These results indicate that PHCE scaffolds increase cell
proliferation after 4 and 7 days when compared to GE controls. It is also evident that the
addition of a mineral coating to GE scaffolds increases cell proliferation on day 4.
The same MTS data was graphed differently to analyze the statistical differences of
cell proliferation on a given scaffold over 7 days (Figure 5.4B). The only scaffold that
recorded a significant difference (increase, p<0.05) in cell proliferation was PHCE after 4
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and 7 days culture. An unexpected result evident in both graphs was the significantly low
(p<0.05) cell proliferation count on PHCE-M scaffolds. As DAPI will confirm in the
following section, cells are abundant and present throughout PHCE-M scaffolds. This
interesting observation poses some unique questions for future studies, “Why doesn’t the
MTS assay register cells on PHCE-M scaffolds?”, “Are cells not proliferating on PHCE-M
scaffolds?”, “Do cells on PHCE-M scaffolds quickly convert to a non-proliferative state?”
When osteoblasts are present in an environment conducive to bone formation, the cells will
stop proliferating and begin to secrete bone matrix. It is known that mature osteoblasts also
have the ability to undergo apoptosis or become integrated within the mineral matrix to
become osteocytes. It is a possibility that the PHCE-M scaffolds contain enough Ca-P such
that osteoblasts are not scrambling to rebuild bone, but are rather content after attaching
and begin integrating with the mineralized scaffold. This could also explain the nonproliferative state of osteoblasts and the low cell count reported by MTS.
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Figure 5.4 - MTS of cells cultured A) on each scaffold at a given time point and B) on a
given scaffold for 7 days.
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5.4.4. DAPI staining
Cell attachment and more importantly, infiltration into all scaffolds, was analyzed
via DAPI staining after dynamic seeding followed by static culture for 1 and 4 days
(Figure 5.5). The control GE scaffolds attached fewer cells than all other scaffold types,
but did show appropriate cell infiltration after days 1 and 4. Cell infiltration into GE
scaffolds is most likely attributed to the dynamic cell seeding method, since in Chapter 3,
cells statically seeded on GE scaffolds primarily remained on the surface. A visual increase
in cell attachment at the surface was observed for GE-M scaffolds suggesting that the
minerals nucleated on the scaffold surface provide additional cell adhesion sites for
osteoblasts. After 4 days in culture, cells were present throughout the entire scaffold
indicating successful cell migration. Both PHCE and PHCE-M showed a large number of
cells present throughout the scaffold on days 1 and 4. This increased cell attachment and
infiltration was also reported for PHCE scaffolds in Chapter 3 using the static cell seeding
method. This suggests that PHCE scaffolds increase initial cell attachment and infiltration
independent of the cell seeding technique. Although there is no visual difference of cell
attachment or infiltration between PHCE and PHCE-M scaffolds, there is a noticeable
increase in initial cell attachment and infiltration when compared to GE and GE-M
scaffolds on day 1. Even though cells on scaffolds are not clearly visible on the SEM
images or detectable on PHCE-M scaffolds via MTS assay, DAPI results confirm the
presence and viability of cells for up to 4 days.
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Figure 5.5 - DAPI staining of mineralized and non-mineralized GE and PHCE scaffolds
after dynamic cell seeding and subsequent static culture for 1 and 4 days.
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5.4.5. Multiplexer analysis of secreted osteoblast factors
After 1, 4, 7, 14, and 21 days of MG-63 cell culture on scaffolds, osteoblast
secretion of osteocalcin, osteopontin, IL-1β, IL-6, and TNF-α were analyzed. At the tissue
level, bone coupling (regeneration and resorption) is regulated through a large number of
cytokines and proteins (some regenerative factors were presented in Table 2.1). These
factors have a complex and overlapping effect such that bone regeneration and resorption
can occur simultaneously depending on the need of the microenvironment. The exact roles
of some factors, such as IL-6, are not clearly identified and have been found to have both
resorbing and regenerating effects. TNF-α is primarily associated as a pro-inflammatory
cytokine secreted by inflammatory cells. However, less commonly known, osteoblasts
have the ability to synthesize and release TNF-α as a local regulator for osteoblast function
[135]. The osteoblast secreted factors analyzed in this study are a mix of bone regenerating
and bone resorbing markers which provide a comprehensive analysis of osteoblast
response over 21 days culture on GE, GE-M, PHCE, and PHCE-M scaffolds. Table 5.1
briefly summarizes some known functions of each of these factors.

Table 5.1 - Role of multiplexer human bone panel analytes in bone remodeling.

osteocalcin

Function
Marker for bone formation. Elevated secretion related
to increase bone formation [136, 137]

Osteopontin Bone resorption [138, 139]
IL-1β
Bone resorption [140, 141]
Bone resorption [142-145]
IL-6
Osteoblast differentiation [146, 147]
TNF-α
Bone resorption [148, 149]
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Multiplexer analysis revealed no traces (reported values below lowest standard) of
osteopontin or IL-1β secretion by MG-63 cells cultured for 21 days on any scaffold type.
These are positive results since both of these factors are associated with bone resorption.
TNF-α secretion was detected in very small quantities (0.2 – 0.4 pg/mL), specifically on
day 1 of GE, GE-M, and PHCE scaffolds (Figure 5.6). The lowest standard was 0.2 pg/mL,
which suggests that the release of 0.2 – 0.4 pg/mL is at the lowest concentration detectable
using the multiplexer. These results suggest that some cells that attached to GE, GE-M,
and PHCE scaffolds secreted low amounts of TNF-α after 1 day culture on scaffolds.
Although TNF-α is associated with bone resorption, the low concentrations detected on
day 1 are not indicative of a bone resorbing response. In the body, bone resorption and
regeneration occur simultaneously. It is possible that some cells attached in certain highly
mineralized areas and began secreting TNF-α to initiate the resorption of that specific area
on day 1. However, since low amounts of TNF-α were only detected on day 1, this
suggests that this may be an initial response of some cells which is no longer the
conditions from days 4 to 21. When comparing TNF-α secretion of all scaffolds on a given
day, there were no significant differences (p<0.05) observed. This shows that on a given
day, there was not a scaffold that induced significant secretion of TNF-α compared to the
others.
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Figure 5.6 - Secretion of TNF-α by MG-63 cells cultured on each scaffold over 21 days.

Analysis of IL-6 cytokine secretion from cells showed some significant differences
when comparing scaffold types as well as time points. After culture for 1 and 4 days, cells
on GE-M scaffolds secreted significantly higher (p<0.05) amounts of IL-6 compared to all
other scaffolds (Figure 5.7A). From days 7 to 21, all IL-6 release was below detectable and
not significant (p<0.05) between scaffolds. Figure 5.7B graphs the secretion of IL-6 and
statistically compares release over 21 days per scaffold type. These results show a common
trend of significantly higher IL-6 secretion on day 1 for all scaffolds. As alluded to in
Table 5.1, the effects of IL-6 within bone remodeling are not totally defined. The literature
supports both theories of increased levels of IL-6 correlating to bone regeneration and
resorption. This study did not investigate the bone remodeling effects of IL-6, but it clearly
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demonstrated that cells seeded on GE-M scaffolds and cells seeded on any scaffold after 1
day secrete significantly higher levels of IL-6.

Figure 5.7 - IL-6 secretion by MG-63 cells comparing A) scaffold types at a given time
point and B) each scaffold over 21 days.
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Secretion of osteocalcin by MG-63 cells was detected for all scaffold types at all
time points suggesting that the cultured cells are responding positively by promoting a
bone regenerative environment. Figure 5.8A below shows the secretion of osteocalcin by
cells on all scaffolds on a given day. There are several statistical differences which vary
over 21 days. Briefly, the highest secretions of osteocalcin were recorded from cells on:
GE & PHCE-M scaffolds on day 1; GE, GE-M, & PHCE-M scaffolds on days 4 and 7;
GE-M scaffolds on day 14; and GE-M & PHCE on day 21. The most noticeable trend with
this data is starting on day 4, cells on GE-M scaffolds consistently secreted high amounts
of osteocalcin over 21 days. Osteocalcin secreted from cells cultured up to 21 days were
also compared within each scaffold type (Figure 5.8B). For GE and PHCE-M scaffolds,
osteocalcin secretion was highest on days 1, 4, and 7. Cells on GE-M scaffolds secreted
lower amounts of osteocalcin on day 1 but then showed significant increases in secretion
on days 4, 7, and 14. Constant levels of osteocalcin protein secretion were observed for
PHCE scaffolds over 21 days. These results suggest that depending on the scaffold type,
MG-63 cells will promote more bone regeneration at different time points within 21 days.
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Figure 5.8 - Osteocalcin secretion by MG-63 cells comparing A) scaffold types at a given
time point and B) each scaffold over 21 days.

Table 5.2 was constructed to summarize the secretion of all factors by MG-63 cells
on all scaffolds on each day. This table compiles and identifies which scaffolds induced the
highest secretion of all factors on each day. For osteopontin, IL-1β, and TNF-α, all
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scaffolds on each day induced the same amount of secretion (little to none). This is a
desired result since these factors are associated with bone resorption. For osteocalcin, GEM scaffolds induced amongst the highest secretion from day 4 to 21, suggesting that these
scaffolds would induce more bone regeneration within 21 days. For IL-6, GE-M scaffolds
induced the highest secretion on day 1 and day 4 (along with PHCE-M). As previously
mentioned, the role of IL-6 in bone remodeling is controversial. Therefore, in this study, it
cannot be concluded if IL-6 relates to bone regeneration or resorption.

Table 5.2 - List of scaffolds that induced the highest secretion of factors at a given day.
Day 1
GE
osteocalcin
osteopontin
IL-1β
IL-6
TNF-α

PHCE-M
GE-M
-

Day 4
GE
GE-M

Day 7
GE
GE-M

Day 21

GE-M

GE-M
PHCE

PHCE-M
-

-

-

-

-

-

-

-

-

-

-

-

-

GE-M
PHCE-M
-

Day 14

Table 5.3 was created to summarize the trends (increase or decrease) of osteoblasts
factor secretion per scaffold over 21 days. All scaffolds showed decreases or low cell
secretion of IL-6 and TNF-α at early time points (day 1 or 4). GE and PHCE-M scaffolds
induced lower osteocalcin secretion after day 7 and 21, respectively. GE-M scaffolds
induced increased levels of osteocalcin secretion after day 1, while cells on PHCE
scaffolds secreted constant levels over 21 days.
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Table 5.3 - Trend of secreted factors from MG-63 cells on scaffolds over 21 days.

osteocalcin

GE
↓ after day 7

GE-M
↑ after day 1

PHCE
constant

PHCE-M
↓ on day 21

osteopontin

-

-

-

-

IL-1β
IL-6
TNF-α

↓ after day 1
↓ after day 1

↓ after day 1
↓ after day 1

↓ after day 1
↓ after day 4

↓ after day 1
constant

Overall, the analysis of secreted MG-63 cell factors suggests that the cells are
responding in a bone regenerative fashion on all scaffolds, as evidence of osteocalcin
secretion. Little to no secretion of osteopontin, IL-1β, and TNF-α proves that the scaffolds
are not influencing the cells to respond in a resorptive manner. Again, the early secretion
of IL-6 may be indicative of early bone regeneration or bone resorption response. In either
instance, IL-6 secretion was only noticed at early time points and diminished after day 1.
Since natural bone has the ability to regenerate and resorb simultaneously, the secretion of
a combination of bone remodeling factors may be detected within the bone
microenvironment. However, this study demonstrates the strong presence of MG-63
osteocalcin secretion (compared to other factors) that is consistent throughout 21 days of
culture on all scaffolds.
5.4.6. Uniaxial compression testing
As previously mentioned in Chapter 4, day 4 of mechanical testing was not
reported as the mechanical properties showed no differences between days 1 and 7 and
significant changes weekly. To analyze compressive mechanical properties of cellularized
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scaffolds, both peak load (N) and Young’s modulus (MPa) for compression were recorded.
Figure 5.9A below graphically displays the peak load of each cellularized scaffold type at a
given time point. This allows us to determine which scaffolds have superior/inferior
mechanical properties at each day. For day 1, GE-M scaffolds had significantly higher
(p<0.05) peak loads to only PHCE scaffolds. By day 7, only GE scaffolds showed
significantly higher (p<0.05) values than PHCE and PCHE-M scaffolds. On day 14 PHCE
scaffolds showed the lowest (p<0.05) peak load values while on day 21 GE-M scaffold
showed the highest (p<0.05) peak load values when compared to all scaffolds. These
results do not show any predictable trends, but more of a variation with scaffold
performance when compared to each day.
To better understand the peak load of each scaffold as it degraded, the same peak
load data above was graphed differently and statistics performed (Figure 5.9B). For GE
scaffolds seeded with cells, day 14 of culture produced significantly higher (p<0.05) peak
load values than at all other time points while day 7 was only higher (p<0.05) than day 1
and 21. This suggests that for GE scaffolds, the cells strengthened the scaffold over 14
days. Since there was no detection of osteopontin, the cells are not resorbing the GE
scaffolds which lead us to believe that the decrease in peak load at 21 days is not attributed
to cell remodeling, but possibly the degradation of the scaffold. For GE-M scaffolds, only
day 7 peak load values recorded different (significantly lower, p<0.05) than all other time
points. There were no significant differences (p<0.05) in peak load values for PHCE
scaffold over 21 days suggesting that the cells remodeling the scaffold were providing a
balance of scaffold degradation and support. For PHCE-M scaffolds, only day 14 peak
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values were significantly higher than day 21 values. Compared to acellular peak load
values presented in chapter 4, there are fewer trends observed. This variation in peak load
for cellular scaffolds is expected since the cells will continuously remodel each scaffold
uniquely by attaching, applying their own mechanical forces, remodeling the scaffold, and
producing matrix.
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Figure 5.9 - Peak load of A) cellularized scaffolds at a given time point and B) of a given
cellularized scaffold over 21 days in culture.
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To compare acellular (Chapter 4) and cellular (Chapter 5) peak load results, data
was combined, graphed, and statistically analyzed for significant differences (Figure 5.10).
Statistics were only performed on data comparing acellular versus cellular scaffold
properties on a given day. For GE scaffolds, only day 21 cellular scaffolds showed
significantly lower (p<0.05) peak load values compared to acellular values. This suggests
that for GE scaffolds, the addition of cells do not influence the compressive peak load
properties until day 21. Comparing acellular and cellular GE-M scaffolds, day 1 reported
no significant difference, day 7 cellular scaffolds had significantly lower (p<0.05) values,
and both days 14 and 21 cellular scaffolds had significantly higher (p<0.05) values than
their acellular counterparts. This suggests that for GE-M scaffolds, the addition of cells
increases the peak load values after longer culture times (14 and 21 days). For both PHCE
and PHCE-M scaffolds, only day 14 cellularized scaffolds reported a different
(significantly higher, p<0.05) peak load when compared to acellular scaffolds at the same
time point. With cells continuously remodeling the scaffolds, it is difficult to extract
relationships. It does, however, appear that at one point (day 14) for PHCE and PHCE-M
scaffolds, the cells are remodeling the scaffold in a fashion that increases the peak load
compressive properties of the scaffold.
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Figure 5.10 - Peak load comparison of acellular and cellularized scaffolds over 21 days.

The second mechanical property that was extracted from the testing data was
Young’s modulus for compression. Figure 5.11A displays the modulus of cellularized
scaffolds at a given time point. It was determined that at each time point, there were no
statistical differences (p<0.05) between the moduli of all scaffolds. This data reveals that
independent of scaffold type, at a given time point all scaffolds exhibit similar Young’s
modulus for compression. The means of Young’s modulus for all cellularized scaffolds
throughout 21 days in culture ranged from 1.9 – 3.8 MPa. Figure 5.11B graphs the same
Young’s modulus data except in a form where statistics can compare the modulus of a
given cellularized scaffold over the 21 days. Only cellularized GE scaffolds at day 21 had
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significantly higher (p<0.05) moduli than day 7 scaffolds. All other scaffolds reported no
significant changes (p<0.05) in moduli over the 21 days in culture.

Figure 5.11 - Young’s modulus for compression of A) cellularized scaffolds at a given
time point and B) of a given cellularized scaffold over 21 days in culture.
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To compare acellular (Chapter 4) and cellular (Chapter 5) Young’s modulus
results, data was combined, graphed, and statistically analyzed for significant differences
(Figure 5.12). As mentioned for peak load combined results, statistics were only performed
on data comparing acellular versus cellular scaffold properties on a given day. For nonmineralized cellular scaffolds (GE and PHCE), the only significant difference (p<0.05)
was noticed on day 21 where cellular scaffolds reported higher modulus values that
acellular scaffolds. This data suggests that after 21 days, the cells are remodeling nonmineralized scaffolds in a manner that ultimately increases the scaffold’s stiffness. GE-M
scaffolds showed no significant differences (p<0.05) while PHCE-M scaffolds only
showed a significantly higher (p<0.05) modulus for day 1 cellular compared to acellular
scaffolds. Overall, the Young’s modulus for compression of mineralized scaffolds
remained unaffected as a result of the addition of cells.
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Figure 5.12 - Young’s modulus for compression comparison of acellular and cellularized
scaffolds over 21 days.

Although PHCE and PHCE-M had similar or lower peak load and modulus values
compared to GE and GE-M scaffolds, the gross physical appearance of the mechanical
integrity of the scaffolds were strikingly different once subjected to compressive
mechanical loading. After subjection to compressive mechanical testing, the GE and GE-M
scaffolds were demolished into pieces while the PHCE and PHCE-M scaffolds remained
intact after complete compression (Figure 5.13). Although these images do not provide any
quantifiable data, it does offer insight to future mechanical integrity studies that go beyond
peak load and Young’s modulus for compression. It is clear that the addition of PRGF,
HA, and CW to gelatin sponges allowed the scaffold to remain intact after maximum
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compression, however, the degree to which each individual component contributed is a
direction of future research.

Figure 5.13 - Example of 21 day cellularized (A) GE and (B) PHCE scaffolds after
complete compression post mechanical testing. GE-M and PHCE-M are not pictured as
their gross appearances were similar to their non-mineralized counterparts.

5.5. CONCLUSION
Lyophilized gelatin sponges were enhanced with PRGF, HA, and CW, cross-linked
during gelation, and subsequently mineralized to create a bone-like surface. This study
presents several analyses of MG-63 cell response to scaffolds and scaffold response to
cells. Chapter 3 concluded that MG-63 cells were viable on scaffolds for up to 90 days.
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Since Chapter 4 determined that PHCE-M scaffolds release about 30% of their original
protein, a basic EDC cytotoxicity assay was performed. It was determined that uncrosslinked EDC in any concentration (from 0.8 – 50 mM) is cytotoxic to MG-63 cells.
Therefore, since cells on scaffolds survived for up to 21 days in this study, it can be
concluded that there is no residual harmful uncross-linked EDC which will affect cell
response. Upon SEM examination of cells on scaffolds, it is believed that the dynamic cell
seeding technique enhances cell infiltration and potentially cell integration with the
scaffolds since individual cells were not discernible on the scaffold surface. Both DAPI
and MTS confirmed the presence and viability of cells cultured on scaffolds. DAPI
imaging showed a noticeable increase in initial cell attachment and infiltration of PHCE
and PHCE-M scaffolds when compared to GE and GE-M scaffolds on day 1. GE-M
scaffolds also attached more cells than the GE control providing mineralized GE scaffolds
with an advantage. MTS cell proliferation results indicated that PHCE scaffolds increased
cell proliferation after 4 and 7 days when compared to GE controls. It is also evident that
the addition of a mineral coating to GE scaffolds increases cell proliferation at day 4.
Analysis of MG-63 protein/cytokine secretion suggests that the cells are responding in a
bone regenerative fashion on all scaffolds, as evidence of osteocalcin secretion. Little to no
secretion of osteopontin, IL-1β, and TNF-α proves that the scaffolds are not influencing
the cells to respond in a resorptive manner. For compressive mechanical testing, cells
continuously remodeled the scaffolds making it is difficult to extract relationships. Some
key observations for peak load included at one point (day 14) for PHCE and PHCE-M
scaffolds, cells remodeled the scaffold which increased peak load. Also the GE-M
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cellularized scaffolds recorded higher peak load values on days 14 and 21. Analysis of
compressive modulus suggests that for non-mineralized cellular scaffolds (GE and PHCE),
only significant increases were recorded on day 21. This data suggests that after 21 days,
the cells are remodeling non-mineralized scaffolds in a manner that ultimately increases
the scaffold’s stiffness. Generally, the Young’s modulus for compression of mineralized
scaffolds remained unaffected as a result of the addition of cells. The comprehensive
results from this study support the notion of mineralizing GE scaffolds to increase cellular
attachment, infiltration, and bone regenerative protein/cytokine secretion. Cellularized
PHCE and PHCE-M scaffolds also report similar advantages as GE-M scaffolds, but also
have compressive mechanical modulus values in the range of native tissues present in the
early stages of bone healing. Visually, after complete mechanical compression, cellularized
PHCE and PHCE-M scaffolds performed superior as they remained intact suggesting their
ability to withstand increased mechanical stress.
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6. CONCLUSION AND FUTURE STUDIES
To certain extents, the human body has the unique ability to repair itself following
injury. However, if the injuries exceed a critical size or level of damage, then surgical
intervention is required to enhance the body’s own reparative process. The field of tissue
engineering focuses on developing viable substitutes that are able to repair and regenerate
the functions of damaged tissue. Specifically, bone tissue engineering can provide
improved bone grafting materials such as a porous, biocompatible, and biodegradable
scaffold capable of sustained release of growth factors and cytokines to promote
osteogenesis. Scaffolds such as these can improve the quality of life in patients by
eliminating common drawbacks of current bone grafting procedures and materials such as
the need for a secondary surgery for an autograft and the lack of biodegradability with
ceramic/metal implants.
Lyophilizing a frozen gelatin solution is one fabrication method that has been used
to create bone graft analogues, as it consistently produces hygroscopic porous scaffolds of
any size with the ability to swell and fill any void space or defect. These freeze-dried
scaffolds also have tailorable degradation rates and the ability to incorporate several factors
(proteins, growth factors, nanofillers, etc.). HA is a popular biocompatible nanofiller which
is incorporated within lyophilized sponges and several other bone tissue engineering
scaffolds. This study investigates the very first attempts of incorporating PRGF and/or CW
within lyophilized sponges. The present study was dedicated to developing a scaffold
intended for bone repair. This biodegradable scaffold was specifically designed to mimic
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the biological, biochemical, and mechanical microenvironment of the early stages of bone
healing. In the present study, the first goal was to fabricate a cross-linked threedimensional porous lyophilized gelatin sponge enhanced with PRGF, HA, and/or CW. We
then investigated the different ways in which these enhancements altered the biological,
mechanical, and regenerative characteristics with the intention of creating a bioresorbable
graft that would have the ability to become completely remodeled into functioning new
bone. Scaffolds were preliminarily evaluated to determine the advantages of various
compositions and cross-linking methods of composite lyophilized gelatin sponges. This
study illustrated that a lyophilized gelatin sponge, incorporated with PRGF, HA, and CW,
demonstrated osteogenic potential when cultured with an MG-63 osteoblast-like cell line.
These scaffolds, further modified through EDC cross-linking during gelation, exhibited
controlled protein release (degradation), increased cellular attachment/infiltration,
remained intact after 90 days in culture, and promoted the secretion of cell-created bone
matrix. This tailorable rate of degradation is critical in a bone repair scaffold, where
scaffold breakdown needs to match the ingrowth of vasculature and new bony matrix to
prevent catastrophic failure. While the overall comparison of scaffolds did not clearly
predict which combinations of PRGF, HA, and CW would induce optimal bone
regeneration, it does give some insight to the advantages of the addition of growth factors
and nanofillers to lyophilized gelatin sponges. The lyophilized sponges containing PRGF,
HA, CW, and cross-linked during gelation (PHCE) performed well in the preliminary
evaluations and were further investigated.
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In an effort to further enhance the bioactivity and biocompatibility of cross-linked
during gelation gelatin (GE) and PHCE scaffolds, SBF treatment was used to create a
bone-like mineral surface on the scaffolds. For PHCE scaffolds, this is similar to the dual
mineralization strategy used in our lab where a scaffold is fabricated with HA and
subsequently mineralized with SBF. GE scaffolds nucleated minerals in more of a sparse
aggregate manner while PHCE scaffolds showed more uniform biomimetic mineralization
across the surface. GE and PHCE scaffolds were also evaluated for the ability to swell and
both demonstrated the ability to swell 50% of their original volume upon hydration. In
addition to analyzing scaffold characteristics, a growth factor profile of PRGF, PRP, and
PPP was obtained to identify which factors were present and at what concentrations. The
highest concentrations of growth factors detected in PRGF and PRP were HGF and VEGFA. The growth factor profile of PPP (1:10) more closely resembled that of PRGF (1 and
0.1 mg/mL), both highly diluted solutions. These factors all have been shown to increase
the formation of bone either through increased vascularization or bone mineral density and
support their incorporation within scaffolds. This study also showed that PHCE-M
scaffolds degraded faster and released 30% of its original protein content over 21 days.
Although PHCE-M scaffolds degraded the fastest, no PRGF growth factors were
detectable after analyzing scaffold release contents. However, multiplexer analysis did
reveal the successful incorporation of PRGF within uncross-linked PHC sponges. As
previously mentioned, an important parameter for tissue engineering scaffolding is the
comparable mechanical properties of the scaffold and the native tissue being regenerated.
The lower compression moduli values of PHCE and PCHE-M scaffolds are comparable to
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moduli values of tissues found in the early stages of bone healing. The creation of these
enhanced lyophilized sponges proved to have sustainable release, osteoinductive, and
mechanical properties that could be conducive for bone graft applications; however, the
bioactivity and cellular response of these materials were not investigated in this study.
These findings suggest that PHCE and PHCE-M scaffolds have potential for use as early
bone healing tissue scaffolds and support future in vitro cellularized studies to assess
cellular responses to the various composite porous sponges.
Finally, the MG-63 cell response to scaffolds and scaffold response to cells was
explored. A basic EDC cytotoxicity assay was performed and determined that uncrosslinked EDC in any concentration (from 0.8 – 50 mM) is cytotoxic to MG-63 cells.
Therefore, since cells on scaffolds survived for up to 90 days (Chapter 3) and 21 days
(Chapter 5), it can be concluded that there is no residual uncross-linked EDC that will
negatively affect cell response. In this study, cells were dynamically seeded on floating
scaffolds in a bioreactor to more appropriately simulate cell recruitment and attachment to
scaffolds compared to the static cell seeding method. Since individual cells were not
discernible on the scaffold surface upon SEM examination, it is believed that the dynamic
cell seeding technique enhanced cell infiltration and potentially cell integration with the
scaffolds. Both DAPI staining and MTS cell proliferation assay confirmed the presence
and viability of cells cultured on scaffolds. DAPI imaging showed a noticeable increase in
initial cell attachment and infiltration of GE-M, PHCE, and PHCE-M scaffolds when
compared to GE controls. This data supports the mineralization of GE sponges and the
incorporation of PRGF, HA, and CW within GE scaffolds. The ability to attach cells
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throughout the entire scaffold at early time points is an attractive quality when considering
scaffolds for any tissue engineering applications where the cells are able to remodel the
scaffold as a unit rather than portions at a time. Cell proliferation results indicated that GEM and PHCE scaffolds increased cell proliferation after day 1 when compared to GE. For
PHCE-M scaffolds, cell proliferation results showed a significant decrease in cell number.
This was a surprising result since DAPI staining confirmed the presence of many cells on
PHCE-M scaffolds at days 1 and 4. Since MTS measures the mitochondrial activity of
proliferating cells, it is possible that the cells attached to PHCE-M are no longer in a
proliferative state. These results propose interesting questions to be answered in future
studies in which alternative methods for cell counting (such as trypan blue) can be
explored. Analysis of MG-63 protein/cytokine secretion suggests that the cells are
responding in a bone regenerative fashion on all scaffolds, as evidence of osteocalcin
secretion. At early time points (day 1), small amounts of IL-6 secretion was detected. IL-6
is debated in the literature and appears to have effects both on bone regeneration and
resorption. Multiplexer analysis also reported little to no secretion of osteopontin, IL-1β,
and TNF-α, which demonstrates that the scaffolds are not influencing the cells to respond
in a resorptive manner. Analysis of compressive modulus suggests that after 21 days, the
cells are remodeling non-mineralized scaffolds in a manner that ultimately increases the
scaffold’s stiffness. Generally, the Young’s modulus for compression of mineralized
scaffolds remained unaffected as a result of the addition of cells. The moduli values for
cellularized scaffolds remained in the low MPa range as found in native tissue involved in
early bone healing. Upon examination after complete mechanical compression, the gross
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appearance of cellularized PHCE and PHCE-M scaffolds performed superior as they
remained intact, suggesting their ability to withstand increased mechanical stress.
The comprehensive results from this study support the notion of mineralizing GE
scaffolds

to

increase

cellular

attachment,

infiltration,

and

bone

regenerative

protein/cytokine secretion. Cellularized PHCE and PHCE-M scaffolds also report similar
advantages as GE-M scaffolds, but also have compressive mechanical modulus values in
the range of native tissues present in the early stages of bone healing. Lyophilized PHCE
and PHCE-M are bioactive, biocompatible, porous, degradable, osteogenic, and
mechanically similar to tissues found in early bone healing. These scaffolds satisfy the
requirements of a bone tissue engineering scaffold and the presented comprehensive results
support future inflammatory bone healing response and eventually in vivo studies.
6.1. Future research
A couple areas of interest for future direction are analysis of nanofiller particle
dispersion throughout the scaffold and chemical analysis of the scaffold surface.
Transmission electron microscopy can be performed on various cross sections of each
scaffold to visually determine the location and dispersal of the nanofillers (HA and CW)
within the scaffolds. Ideally, sonication of these particles prior to gelation achieves a
homogeneous dispersal of HA and CW throughout the scaffold. Very preliminary
experiments have been performed to analyze the chemical composition of the scaffold
surface. Energy dispersive x-ray spectroscopy (EDS) was performed on the original GE
and PHCE scaffolds to determine if the incorporation of the nanofillers (particularly HA)
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are detected on the surface. Figure 6.1 illustrates the SEM image and corresponding EDS
analysis for both GE and PHCE scaffolds. EDS was performed in two different areas
within the sample to ensure homogeneity (only one is reported below). Defined peaks of
carbon and oxygen were recorded for both scaffolds. This could be attributed to the carbon
coating used to prepare the samples and the fact that the primary material of these scaffolds
is gelatin (chemical structure of carbon, hydrogen, oxygen, and nitrogen). For the GE EDS
spectrum, chlorine and sulfur were also detected. This is thought to be the result of the
presence of residual ions left behind by the DI water (which when filtered, did not entirely
remove ions present in the standard tap water). The more defined chlorine peak is more
likely a result from the detection of EDC cross-linking. EDC has a chemical composition
of carbon, hydrogen, nitrogen, and chlorine elements. In either instance, the GE EDS
spectrum was used as a control. Upon PHCE EDS analysis, elemental peaks of calcium,
phosphate, and sodium (smaller peak) are detected. This suggests that HA is successfully
incorporated within the scaffold and present to some degree on its surface. EDS was also
performed on mineralized samples, however the results were not consistent enough to draw
any conclusions. The chemical analysis of a mineralized scaffold is of interest for future
studies.
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Figure 6.1 - SEM and EDS analysis of GE (A and B) and PHCE (C and D) scaffolds.

In addition to surface characterization, degradation will be more appropriately
assessed through a variety of experiments analyzing specific components. First the release
of gelatin, PRGF, and Ca-P, will be studied individually to determine how the scaffold is
degrading and which contents are being released. The presence of calcium on the scaffold
surface can be quantified over time which will provide insight to the scaffold mineral
content as components are being released. The combination of these experiments provides
a more comprehensive analysis of scaffold degradation. Other future experiments include
analysis of porosity, detection of RANKL for a more general understanding of osteoblast
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bone remodeling signals, and the potential application of these scaffolds for cartilage tissue
engineering (since mechanical properties are within the range of native cartilage).
To more appropriately assess each scaffold’s ability to promote bone healing, the
response of inflammatory (monocytes/macrophages) and primary (osteoprogenitor) cells
will need to be explored. As previously mentioned, bone healing consists of three main
stages: inflammatory, repair, and remodeling. One of the main interests of this study is to
determine the scaffold’s ability to influence inflammatory cell behavior (cells present in
the first stages of bone healing). This includes the attraction and differentiation of
monocytes into macrophages, the subsequent polarization of macrophages to a proinflammatory (M1) or pro-regenerative (M2) state, the characterization of growth factors
released by macrophages, and the osteoinductive capability of these growth factors with
respect to MSC differentiation into osteoblasts. It is known that macrophages must
transition to the M2 phenotype to facilitate proper tissue remodeling after disinfecting and
debriding a site of injury [150]. Clinically, scaffolds can be fabricated with a quick
turnaround from a patient’s PRP blood draw to fabrication of the sponges. The hypothesis
of this future study is that the PHCE sponge will serve as a bioactive structure to facilitate
sustained delivery and presence of PRGF, differentiation of monocytes into proregenerative (M2) macrophages, and macrophage secretion of osteoinductive growth
factors which will result in the differentiation of osteoprogenitor cells (such as
mesenchymal stem cells) into osteoblasts. The end goal of this future work will be to
create an implantable bone healing microenvironment mimicking analogue containing the
necessary cues to integrate properly with a patient’s own bone which has been injured.
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